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Animal models have been recognized for the valuable roles they serve in both
animal and human medicine. Dogs share many of the same naturally occurring tumors as
humans including osteosarcoma, lymphoma, and mammary tumors. In addition, dogs
share the same environment as humans, have a shorter lifespan, and often have a quicker
progression of disease, making them an attractive model of human disease. Platelets are
small anucleate cell fragments that have essential roles in hemostasis, angiogenesis, and
wound healing, and, more recently recognized, roles in development, survival, growth,
and metastasis of various cancers. Their roles in angiogenesis has proven to be both
directly and indirectly linked to tumor growth due to the angiogenic roles they play in the
development of tumor blood supply.
Being able to study the interactions and mechanisms between platelets and tumor
cells at the protein level, through proteomics, would allow great insight into the effects of
platelets on tumor cell behavior as well as potential biomarker identification and
therapeutic development. The objective of this research is to integrate the roles of canine
platelet proteins into a better understanding of the effects and interactions that platelets
have with different tumor cells while utilizing the canine model of neoplasms commonly

affecting their human counterparts. The first study in this research describes an efficient
technique developed for the purification of canine platelets from clinically relevant
volumes of whole blood with high platelet recovery and minimal contamination from
other blood cells. The second study describes a non-electrophoretic detergent
fractionation technique used for the digestion of canine platelet samples for proteomic
analysis as well as description of the proteomic findings for the normal canine platelet.
Lastly, the third study describes the proteomic analysis of proteins differentially
expressed by canine osteosarcoma and mammary tumor cells following incubation with
canine platelet lysate in vitro. Overall, findings of this research support the canine model
of human cancers and provide comprehensive information regarding canine platelet
proteomics as well as novel efficient techniques that aid the future of canine platelettumor cell interaction research
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INTRODUCTION
Much of the current research into human disease relies heavily on animal models,
with some of the most notable and most recent models used for cancer research. These
animal model systems utilize the animal as well as cancer cell lines for studying
biochemical pathways, progression and advancement of diseases, as well as development
and response to various therapeutic modalities, both in vitro as well as in vivo [1]. In
more recent years, the canine model for human disease has been recognized as a valuable
model because dogs share many of the same naturally-occurring neoplasias as well as
treatment responses, in comparison to the commonly used mouse and rat models in which
tumors are often induced using genetically altered subjects. These rat and mouse models
often fall short in their ability to translate from the bench top to clinical application. Due
to their shorter lifespan, trends for more rapid disease progression, as well as sharing the
same environment as humans, the dog offers a multitude of benefits to the animal model
system beyond having similar neoplasias to people [2, 3, 4]. This year, more than 1.6
million people are expected to be newly diagnosed with cancer in the USA, along with
roughly 600,000 cancer-related deaths [5]. With these incidences in mind, early detection
modalities, as well as tumor-specific treatments, are essential in the future of cancer
research.
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Annually, roughly 6 million dogs are diagnosed with cancer, a majority of which
are similar to those cancers affecting their human companions [6]. Canine lymphoma,
osteosarcoma, and mammary tumors are three naturally-occurring cancers that share a
multitude of similarities with their human equivalents, ranging from clinical presentation,
tumor metastasis, diagnostic findings, histopathologic assessment, treatment protocols
available, as well as prognosis [7, 8, 9, 4]. Canine mammary tumors have long been
utilized as a valuable model in studies related to breast cancer in women due to their
similarities clinically as well as molecularly [10, 11, 4, 12].
Cancer itself is a multifactorial disease involving a number of dysregulations in
cell function and cell signaling. Research has only scratched the surface in identifying
and understanding the pathophysiology and underlying mechanisms involved in each
different tumor type’s development, survival, and proliferation, as well as modalities to
effectively treat and prevent tumors from occurring. One of the most recently recognized
cells discovered to have potentially valuable involvement with cancers is the platelet. The
platelet is an anucleate small cell fragment produced from megakaryocytes, mostly at the
level of the bone marrow, that has been recognized to have novel roles in the body, and
functions in different diseases beyond just hemostasis and wound healing. Research
findings have linked platelets to vital roles in angiogenesis and immune surveillance.
Interestingly, platelets have been suggested to play a role in aiding tumor cell ‘cloaking’
from the immune cells within the vasculature to aid in tumor metastasis at distant sites
[13]. Additionally, a subpopulation of proteins stored within platelet granules termed
‘angiogenic factors’ are utilized in angiogenesis, the process of generating new blood
vessels [14]. Angiogenic factors have been shown to have multiple roles in cancer cell
2

survival and tumor growth, as studies have shown that additional blood supply is needed
for tumor growth greater than 3mm in diameter [15]. Studies on the effects of angiogenic
factors in cancer have produced conflicting results at times [16]. Many studies have
shown pro-tumorigenic effects with upregulation of proangiogenic factors and downregulation of antiangiogenic factors that are present or induced [17, 18, 19, 20]. In
addition to angiogenic protein effects on cancer, platelets and their products have been
shown to have varying effects on cancer cell migration, survival, proliferation, and
metastasis depending on the cancer type and species being studied [21, 17, 22, 23].
One of the most important aspects of researching platelets and their various
effects in different circumstances and disease processes is the purity of the sample
obtained, whether the platelets are derived from human or canine subjects. In human
platelet studies, leukocytes were shown to have 65-fold more protein and 12,500-fold
more mRNA than platelets [24, 25]. Eliminating contaminating leukocytes from platelet
samples is important for obtaining results certain to be caused by or due to platelets
themselves. This is most critical in research dealing with any of the ‘omics’ technologies,
including proteomics. For proteome studies, which is the study of a set of proteins
encoded for by a given genome, samples must contain only the cell or subject of interest
in order to avoid erroneous results from contaminating cells and their protein products.
Protein numbers far exceed the number of protein-coding genes, therefore proteomics
provides a valuable means of analyzing proteins involved in various cellular mechanisms
and interactions as well as those involved in disease pathology and potential therapeutic
strategies. Using proteomics in cancer research will allow the description of tumorspecific profiles at the level of the protein which could then allow the identification of
3

potential biomarkers for use in future disease detection, relapse, and therapeutic
responses [26]. Research into the interactions and effects of platelets with various cancer
types along with the protein profiles and information obtained from highly detailed
proteomic studies will offer valuable information into cellular mechanisms, disease
behavior, diagnostic characteristics, potential therapeutic options, as well as prognostic
indicators specifically tailored to the tumor type in question.
Accordingly, the objective of this research is to employ and justify the dog as a
valuable model of human disease while highlighting some of the significant effects and
roles platelets play in cancers common to both canines and humans.
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LITERATURE REVIEW
Animal Models of Cancer
Despite the ever-increasing number of technological advancements in these
modern times, slow progress is being made to uncover the genetic basis of complex
human diseases. This is primarily attributed to the diverse amount of genetic
heterogeneity that exists [1]. According to the American Cancer Society, cancer is the
second most common cause of death in people in the United States. More than 1.6
million people are expected to be newly diagnosed with cancer across the USA in 2017,
along with approximately 600,000 cancer-caused deaths predicted to occur [2]. Earlier
detection capabilities along with more effective treatment modalities are necessary to
combat this deadly disease. Ongoing research into tumor-specific molecular targeting
have allowed for progress to be made in this direction. Most current research in human
diseases genetics, most notably in the area of cancer research, relies on animals as models
for disease by utilizing animal and cancer cell lines in vitro and in vivo to study
biochemical pathways associated with different cancer cells [3].
In vitro models provide many advantages for disease research in their ability to
provide conditions that can be strictly controlled, homogeneity, and ease of
reproducibility for determining understandings of genetic mechanisms. Beyond that,
though, in vitro models quickly reach limits including adaptation of cell lines to the
8

conditions in vitro, mutation development in cell lines from continued cell splitting and
preservation, and a lack of the naturally occurring tumor environment [4]. Some research
into the production of three-dimensional models for in vitro use has been performed [5].
The use of in vivo animal models for cancer research allows for rapid translation
of therapeutic investigations and clinical trials to take place from the lab bench to the
patient. The most common of these animal models is the mouse, which has allowed great
progress to be made in the understanding of molecular mechanisms and pathways as well
as the function of numerous genes and proteins in vivo [6]. Mice provide many
advantages to modeling human disease due their short gestation length and small size,
both of which allow for quick turnover and minimal expense and space required for
studies to be conducted. Since mice have been used extensively in animal model studies
for years, there are many technologies developed to allow alteration and manipulation of
specific genes of the animal or a subset of cells [7]. The most common forms of rodent
models include xenografts or those with genetically-induced cancers [8]. Xenograft
models are genetically immunocompromised (athymic nude mice or SCID mice most
commonly) rodents that are later transplanted with cells from a human or animal cancer
under the skin or into a particular organ [8, 9, 10].
While boasting advantages such as low expense and the ability to aid the
development of cancer therapeutics and imaging modalities, rodent models quickly reach
their limitations on their ability to easily translate to clinical applications in human cancer
[11, 12]. The most notable cause for this disadvantage is the fact that laboratory-bred
mice are deficient in aspects of their immune system, therefore not allowing accurate
representation of the normal physiology seen in the cases of naturally occurring cancers
9

that are seen in humans or other species like the dog [13]. Genetically engineered mice
have provided good models of human cancer for the development of novel therapeutics
and pre-clinical studies through the selective suppression of tumor suppressor genes and
specific oncogene induction, but have limitations due to an inability to control the overall
level and pattern of gene expression [14, 12]. In addition, in comparison to the genetic
alterations able to be made in mice, human diseases are almost always polygenic in
nature. Genetic manipulation in the mouse may only involve a handful of genes or often
involve alterations to the environmental conditions to cause differential gene expression
in specific inbred strains. As can be expected, these alterations and genetic changes are
quite different than those occurring in naturally occurring human diseases [1]. Overall,
mice can serve as good models for initial human disease research, but the differences in
genetic makeup and interactions create a need for a model that is more comparable to
natural human disease.
Although rodents offer advantages in their use as animal models by their small
size, short lifespan, short gestation length, and inexpensive maintenance, the successful
translation rate for research originating in rodent models to clinical cancer trials in
humans is less than 8% [15]. Companion animals (dogs and cats) offer many distinct
advantages as animal models in their similarities to various cancers shared with humans,
including a relatively high incidence of naturally occurring cancers, similar biological
behaviors of cancers, the similar response to therapies administered, and similar
responses to cytotoxic agents as those that occur in humans. The fact that companion
animals have a shorter lifespan and more rapid progression of disease than humans are
additional factors to support the companion animal model [16, 17, 18]. In addition to this,
10

clinical trials and information gained from the use of companion animal models in
oncology benefits the diagnostics and therapeutics to be used in both human and
veterinary medicine. Nearly 1.7 million people are predicted to be newly diagnosed with
cancer in the USA in 2017 [2]. In veterinary medicine, about 6 million dogs are
diagnosed annually with cancer, providing ample opportunity for the study of naturally
occurring tumors similar to those that occur in humans [19].
Canine Model of Cancer
Dogs develop tumors at twice the rate of their human counterparts. Tumors that
naturally occur in dogs have been proven to have greater clinical and biological
similarities to human cancer compared to other animal models [18, 20]. Dogs share many
similarities with humans in the cancers they develop naturally including the age of onset,
rates of reoccurrence and metastasis, response to similar therapies utilized, and histologic
appearance [21]. Paoloni et al also described that the same alterations in tumor oncogenes
and tumor suppressor genes occur for both humans and dogs [21]. The similarities shared
between canines and humans extend all the way to the genetic level. Researchers have
illustrated that some of the gene families and their associated cancers had a closer
relationship between humans and canines than those for any other species [22].
Molecular cytogenetic analysis of canine hematologic malignancies revealed evidence of
ancestral aberrations at the level of the chromosome between humans and canines [23,
24]. Cancers that commonly affect dogs that would make excellent models for similar
human cancer include lymphoma, head and neck carcinomas, bladder cancers,
osteosarcoma, mammary cancers, prostate cancer, lung cancer, and melanoma [21, 25].
Recently, a number of similarities were described between canine and human
11

pheochromocytomas and paragangliomas, and suggested the dog as an excellent model
for pathways and comparative studies [26]. Researching and testing treatments in
naturally occurring cancers (as well as other diseases) in dogs does not create the
troublesome ethical issues commonly encountered with animal models in which disease
is experimentally induced. Alternatively, dogs have also been suggested for the valuable
role they could play in the link between mechanistic studies in mice and clinical disease
applications in humans [27]. Overall, the canine model is more robust and ethical when
compared to mouse and rat models.
One of the most common neoplasias affecting dogs, lymphoma, makes up
approximately 20% of all canine cancer diagnoses and 80% of canine hematopoietic
cancers [28]. Arising from unregulated lymphocyte proliferation in a multitude of organs
associated with the lymphatic system (spleen, bone marrow, lymph nodes, intestines),
lymphomas are notorious for their tendency to be highly metastatic, with a high rate of
recurrence regardless of treatment. Similarities between canine and human lymphoma
include their clinical presentation, genetic mutations, tumor biology, and tumor behavior,
which makes the dog an excellent model for disease progression and therapeutic
modalities [20, 29]. Current treatments utilizing combined chemotherapeutic agent
protocols including vincristine, cyclophosphamide, doxorubicin, and prednisone are used
for lymphoma treatment in both human and canine patients [30], and recurrence is
common and resistance is becoming an increasing concern. Response rates to these drug
combinations are reported to be 86-91% [31, 32], although most dogs will eventually die
due to the recurrence of a drug-resistant form of lymphoma. The canine model has
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allowed for the development of new treatment modalities like asparaginase [33], a
commonly used ‘rescue’ drug in veterinary medicine after lymphoma relapse occurs.
Environmental causes of cancer, e.g. tobacco smoke, have also been a point of
similarity discovered between dogs and humans, most notably in cancers of the head and
neck as well as lung cancers [34]. Head and neck cancers make up approximately 20% of
the oral malignancies seen in dogs [35]. In humans, these squamous cell malignancies are
highly aggressive and invasive with limited treatment efficacy [36]. Although the
prevalence of lung cancer in canines is low (1%) [18], while the incidence represents
approximately 27% of all cancer diagnoses in humans [2], various studies have linked an
increased in respiratory malignancies in dogs to exposure to cigarette smoke [37]. Dogs
can serve as a valuable model for human cancers such as these to study the effect on
environmental factors like tobacco smoke in carcinogenesis as well as for diagnostic
modalities and treatments.
Canine Osteosarcoma
Background
Osteosarcoma (OSA) is the most common primary bone tumor occurring in dogs
[38], as well as the most common bone tumor affecting children and adolescents [2]. The
incidence of OSA is significantly greater in dogs than humans. Roughly 10,000 new
cases of OSA are identified in dogs each year [39]. In humans, more than 2,500 new
cases of primary bone cancer are diagnosed annually [20]. Occurring much more
frequently than in humans, the estimated incidence of canine OSA is approximately 13.9
per 100,000 [40] compared to the human incidence of 1.02 per 100,000 [41]. Making up
85-98% of all bone tumors found in dogs, OSA is usually found in giant and large breed
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dogs such as Great Danes, Rottweilers, German Shepherds, Dobermans, and Greyhounds
[42]. These large and giant breeds have been reported to have a 61-fold greater risk of
developing OSA compared to other breeds [43]. A bimodal age distribution is shared in
both canine and human OSA [20]. OSA most commonly affects dogs 6-10 years old but
has also been reported in very young dogs [44]. Along with a greater occurrence, canine
OSA is much more aggressive than human OSA. Regardless, the same treatment
modalities are utilized in both humans and dogs [45]. A predilection for greater
occurrence in males has also been reported in the literature for both humans and dogs [46,
47, 48, 49, 50, 51], along with an increased prevalence in dogs that have had
gonadectomies performed [52].
As is seen with their human companions, the most common site for OSA in dogs
is in the metaphyseal region of long bones (75%) [53]. In dogs, OSA occurs more
commonly in the front limbs than in the hind limbs. The distal radius and the proximal
humerus are the two most common locations where OSA lesions are found in dogs [54,
55]. In human patients, the most common sites for OSA lesions include the distal femur
and proximal tibia [55]. The exact etiology behind OSA in either species is still unknown,
but mutagenic effects including radiation, trauma, and genetics are all potential risk
factors in dogs [56, 57, 58].
Clinical Signs & Diagnostics
Upon presentation, the majority of canine OSA patients initially present with
general signs of lameness that may or may not include the presence of pain at the time of
examination, along with localized swelling at the affected site. Due to a common location
of tumors occurring at the level of the knee, signs are often attributed to sports injury
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initially. Based on the stage of disease and activity level of the patient, pathologic
fractures may result in a sudden worsening of the lameness and instability at the fracture
site may be noted.
Radiographs of the affected limb can aid in diagnosis but, ultimately,
histopathology is necessary for definitive diagnosis via biopsy of the tumor site for
histopathologic assessment [59, 60]. On radiographs, an aggressive and destructive
metaphyseal lesion is often present, and can be lytic and/or blastic in nature [61]. There is
often evidence of a characteristic lesion at the tumor edge termed the ‘Codman’s
Triangle’ that occurs due to the production of new subperiosteal bone and periosteal
lifting in aggressive bone lesions [62]. Histologically, canine and human OSA is a
malignant mesenchymal tumor that produces an osteoid matrix throughout.
Once a tentative or definitive diagnosis of OSA is made in either canine or human
patients, chest radiographs are recommended to assess for the presence of pulmonary
metastasis, as the presence of visual metastatic sites within the thorax can greatly impact
staging, prognosis, and treatment options. Only 15% or less of dogs with OSA have
pulmonary metastases detectable on radiographs, although studies have shown that occult
metastatic disease is present in approximately 90% of dogs at the time of presentation
[63]. Advanced imaging such as CT or MRI is now being recommended and utilized for
surveillance of metastatic disease because of their ability to identify smaller foci that may
be undetectable via radiographs [64]. In canines, staging offers important prognostic
determination as well as response to treatments. Stage I OSA describes a patient with a
low-grade lesion with no evidence of metastasis. Stage II OSA consists of high-grade
lesions without evidence of metastasis, while Stage III OSA has metastatic disease
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present at the time of diagnosis. Compartmentalization of staging exists for Stage I and II
OSA consisting of intracompartmental (A, tumor limited to the bone) and
extracompartmental (B, tumor extended into nearby structures). The majority of canine
OSA patients are diagnosed as having Stage IIB OSA at the time of presentation [65].
Pathophysiology
OSA most commonly (75%) occurs in the appendicular skeleton in both human
and dog patients [53]. Canine OSA occurs more often (64%) in the front limbs than the
hind limbs, with the most common locations including the distal radius, proximal
humerus, distal femur, and proximal tibia. In humans, the distal femur and proximal tibia
are the most common locations for OSA lesions [55]. Although less common, the axial
skeleton (skull and ribs) as well as extra-skeletal sites (muscles, adrenal gland, eye,
gastric ligament, ileum, kidney, liver, spleen, testicle, vagina) have also been affected in
various canine cases reports [66, 67, 68].
The majority of dogs (90%) and humans (80%) with OSA have been shown to
have pulmonary metastasis at the time of diagnosis, whether or not those lesions are
visible on imaging at the time [63, 55]. The pulmonary parenchyma is the most common
site of metastasis for both canine and human OSA [53, 38, 55]. Although less common,
metastatic lesions have also been reported to occur in the bone or soft tissue structures
including regional lymph nodes or internal organs like the spleen and/or liver [55, 69].
Dogs that have metastases present in the lymph nodes have much shorter life spans (48
days) in comparison to those that do not (318 days) [70], and humans with regional
lymph node metastasis have a very poor prognosis [55].
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Genetically, human and canine OSA have a 75% aneuploid DNA index with
multiple shared genetic alterations [64]. Many genes associated with human OSA have
been linked to canine OSA as well, including ezrin (EZR), met proto-oncogene (MET,
hepatocyte growth factor), phosphatase and tensin homolog (PTEN), retinoblastoma 1
(RB1), tumor protein 53 (TP53), and v-erb-b2- erythroblastic leukemia viral oncogene
homolog 2 (ERBB2) [71]. Similar alterations to the common tumor suppressor gene, p53,
have been found in both human and canine OSA [72]. Similarities are also shared at the
level of OSA DNA structural changes between humans and dogs. Studies have described
the OSA found in both humans and dogs to have ‘highly complex and chaotic
karyotypes’ due to the various imbalances of genes for oncogenes and tumor suppressor
genes (e.g. MYC and KIT genes) [73]. Aside from genes, elevated levels of vascular
endothelial growth factor (VEGF), a well-studied proangiogenic factor, present in the
plasma of human cancer patients correlates with a negative prognosis [74, 75]. In
angiogenic studies with canine OSA, plasma levels of VEGF negatively correlated with
the disease-free interval [76].
Treatment
In both humans and canines, treatment for this highly malignant neoplasia
includes limb amputation in combination with chemotherapy. Standard chemotherapy
protocols in dogs consist of 3 to 6 cycles of a platinum- or doxorubicin-based regimen
[77, 78, 46, 79, 80, 81, 82]. In humans, chemotherapeutic protocols can take place for up
to one year [55]. Using treatment programs regarded as standard of care, the survival rate
for canine patients at one year is less than 50%, and is less than 20% at two years [63].
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The five-year survival rate in human OSA patients is less than 20% [83], and more than
30% are reported to be unresponsive to chemotherapy [84].
Three of the most commonly used cytostatic drugs used to treat OSA in dogs are
carboplatin, cisplatin, and doxorubicin. In the case of cisplatin, interesting results were
observed by Straw et al 1991, in which cisplatin increased the median survival time of
dogs treated with the drug after amputation compared to those that only had amputation
alone as the treatment, but that the drug had no effect on inhibition of metastasis [82]. In
a study by Moore et al in 2007, 303 dogs with appendicular OSA were assessed for the
efficacy of doxorubicin. The study found that doxorubicin administration via multiple
doses (usually five doses total, once every two weeks) slowed the rate of metastasis with
a 1-, 2-, and 3-year median survival time of 35%, 17%, and 9%, respectively [85].
Similar results were found with the use of carboplatin. Although none of the drugs
completely inhibit metastasis, they are successful in prolonging the life of the patient
being treated. In the treatment of human OSA, the chemotherapeutics associated with the
greatest and most consistent activity include cisplatin, doxorubicin, high-dose
methotrexate (with leucovorin rescue), and isofosfamide (with or without etoposide) [86].
Alternative stand-alone chemotherapy treatments are available, including
lobaplatin and ifosfamide, but have been shown to have limited anti-tumor effects overall
[87]. Many chemotherapy protocols used today enlist the help of multiple cytostatic
agents used on an alternating basis to increase the effectiveness of each drug (eg.
Wisconsin-Madison protocol). Interestingly, some studies conducted on dogs with OSA
showed no significant advantage to multi-drug protocols when compared to
monotherapies [88, 89, 90, 91, 92]. Research by Selmic et al in 2014 showed that
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combining multiple drugs (like carboplatin along with doxorubicin) did not increase the
median survival time [92]. Other studies demonstrated that monotherapy with carboplatin
prolonged the disease-free interval compared to treating with both carboplatin and
doxorubicin together on an alternating schedule [93, 94]. One practical advantage to
multi-drug therapy in dogs with OSA, though, is the prevention or minimization of
negative side effects, and multi-drug therapy should be a consideration when looking at
the long term effects on patient quality of life during treatment [95]. In human treatment,
multi-drug protocols (usually involving three agents) are considered the standard of care,
along with surgery [86]. Additionally, treatment plans for human OSA often involve the
use of neoadjuvant (pre-operative) chemotherapy which has been shown to increase the
disease free interval and survival of patients with non-metastatic disease [96]. This is not
often performed in canine OSA patients, likely due to the advanced state of disease often
present at the time of diagnosis, and surgery is often the first initial step in treatment
followed by chemotherapy.
An alternative to limb amputation is limb-sparing surgery, a technique in which
the dog has played a valuable role in development and research of various surgical
techniques, recovery, and outcome for use in human medicine. For these procedures, the
tumor-infiltrated bone is excised, while the remaining bone is reconstructed to preserve
the limb. For these procedures, internal and/or external fixation via endoprotesis (metal
implant), cortical allografts, or external fixators is performed. Research in dog procedures
revealed that the use of bone cement placed in the marrow during procedures utilizing
large allografts reduced loosening of the implant as well as fracture of the allograft, and
improved healing rates [97]. According to Liptak 2006, the type of implant for fixation
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has no effect on failure of the reconstruction or the risk of post-surgical infection
although, in comparison to limb amputation, there is an increased risk of post-operative
complications as well as the increased time under anesthesia and higher expense [98].
Most commonly, though, complications including infection, fracture of the graft or
implant, and tumor recurrence occur when limb-sparing procedures are performed. In
dogs that undergo limb-sparing surgery for OSA treatment, the recurrence rate is 10-20%,
while the human rate is approximately 5% [55]. Aside from these complications, limbsparing procedures do provide a good alternative for owners resistant to the idea of a limb
amputation [97, 99].
Palliative care is not recommended as the primary treatment option, but may be
utilized in cases when dog owners do not wish to pursue aggressive treatment due to
personal or financial limitations. The goal of palliative treatment is to control the pain
associated with the tumor while having no effect on the progression of the disease. For
this, radiation-based therapy is an effective means for symptomatic treatment of local
bone pain in both humans and dogs with OSA by its ability to reduce inflammation,
induce tumor cell necrosis, stimulate replacement of fibrous tissues, and stimulate woven
bone formation [100]. Analgesic regimens combining the use of opiates and NSAIDs are
often utilized with moderate efficacy in the controlling of pain associated with OSA
[101].
One of the biggest issues facing canine and human OSA patients are metastases
that occur in the lungs before amputation of the limb, and frequently before detection is
possible. In cases where limb amputation was the sole treatment, the most common cause
of death in canine and human patients was diffuse pulmonary metastasis [102]. The main
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purpose of additional chemotherapeutic treatment protocols is to reduce the burden of
micrometastatic disease present [103].
Canine and human OSA share similarities in clinical presentation, tumor
histopathology, metastatic sites, and survival rates, making the dog an excellent disease
model [104]. Dogs have already made contributions to both species in studies developing
and improving limb salvage procedures, techniques that are now utilized in humans and
animals with severe bone lesions like the ones caused by OSA [105]. Future treatment
strategies currently under investigation, some of which utilize dog models, include
molecular targeting of metastasis, markers of chemoresistance, and agents to stimulate
the immune system directly. Previous studies in canine OSA patients have shown that a
macrophage activator, muramyl tripeptide (MTP), had a positive effect on survival, a
result that was shared in subsequent clinical trials in human patients [106, 107, 108, 109].
Prognosis
For both canine and human patients, those that present with evidence of
metastasis at the time of diagnosis have a worse prognosis compared to those that do not
[110, 111, 112, 63]. In cases where metastatic disease has been present at the time of
diagnosis, the patient’s response to chemotherapy is greatly reduced or absent, showing
no efficacy at improving survival [113]. Some studies have shown benefit to performing
surgical removal of the pulmonary metastatic sites (pulmonary metastesectomy) [114].
Although rarely performed in dogs due to diffuse nature of pulmonary metastatic sites,
removal of pulmonary metastases in humans is recommended when possible and has
been shown to significantly improve survival [115].
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In dogs with OSA, prognosis has also been linked directly to alkaline phosphatase
(ALP) levels, and histologic grade, as well as microvascular density [116, 117, 118, 119].
Elevated ALP levels in dogs with OSA correlate with a negative prognosis and shorter
survival times by roughly 50%, regardless of combined surgical and chemotherapeutic
treatments [116, 117]. ALP is regarded as one of the most valuable diagnostic serum
biomarkers in human OSA [120, 121], with increased levels associated with higher tumor
burdens. While histologic grade subclassifications of OSA are still being studied for their
significance in prognosis [53, 122], cellular pleomorphism, mitotic figures, tumor matrix,
cellularity, and the percentage of necrosis present have all been linked to the metastatic
behavior of OSA [123, 118]. Dogs with lower tumor grades (grade I or II) often have a
longer disease-free interval and survival time than those dogs with grade III OSA. In
terms of vascular density in dogs with OSA, one study revealed that higher vascular
density of the primary tumor was present in dogs with metastatic disease detectable at
diagnosis [119]. Evidence of tumor necrosis following chemotherapy administration has
been correlated with local tumor control in dogs, although no distinct correlation has been
made with its link to time to metastasis [124].
While OSA most commonly affects middle-aged to older dogs, those cases where
OSA was diagnosed in young dogs often had more aggressive OSA with shorter survival
times [102]. This phenomenon has also been documented in humans [125, 126, 127, 128,
129]. In addition, large tumor size, dogs weighing over 40kg, and tumors affecting the
proximal humerus have been associated with a worse overall prognosis [130, 131, 122,
46].
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Frequent follow-up chest radiographs are recommended for monitoring for
pulmonary metastasis. CT imaging is a more sensitive method for early detection of
metastasis to the lungs [132], but has a higher expense and is not as readily available to
patients or clinicians. Ultimately, more in vivo and in vitro studies must be performed to
assess effective ways at increasing patient survival and eliminating tumor metastasis.
Canine Mammary Tumors
Background
Tumors of the mammary tissue are the most common tumor occurring in intact
female dogs (52%) [18], with over half of them being malignant [134, 135, 136, 137,
138]. Breast cancer is the second most commonly diagnosed cancer in women, with over
200,000 new cases to be diagnosed in 2016 according to the American Cancer Society
[2]. For both human and canine patients, malignant mammary tumors have a tendency to
recur after being surgically removed, and may metastasize to distant locations such as
lymph nodes, liver, or lung [139]. Some breeds have been documented to be more
commonly affected by mammary carcinomas, including dachshunds, cocker spaniels, toy
poodles, German shepherds, and various mixed-breed dogs [140]. Other factors that may
play a role in the location and incidence of the different tumor types include the age of
the dog, sex, and geographic location [18].
Multiple similarities are shared between canine and human mammary tumors,
including dependence on hormones, metastatic patterns, age of onset, and environmental
causes [18]. For roughly the past forty years, dogs have been used successfully in
modeling comparative studies with human breast cancer research [141, 142, 18, 143] due
to these clinical as well as molecular similarities.
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Clinical Signs & Diagnostics
Most canine mammary tumor patients present with a history of one or more
palpable and/or visual nodule(s) or mass(es) identified along a mammary chain.
Occasionally these may be an incidental finding on physical examination. With
inflammatory and/or metastatic forms of disease, there may be signs of systemic illness
or metastatic site-specific signs (e.g. lameness due to metastasis to bone). Depending on
the extent and stage of the disease at the time of presentation, there may be multiple
different nodules consisting of one or more particular tumor type. The caudal mammary
glands are more often affected than the cranial glands. Reports of multiple different
tumor types occurring within a single mammary gland have also occurred. Human breast
cancer patients are often diagnosed much earlier in the course of disease via utilization of
breast cancer screening tests (eg. mammograms, familial susceptibility testing), but
detection can also occur in a manner similar to dogs, where prominent lumps or swellings
are noted in the mammary tissue or local lymph nodes [144].
For either species, signs consistent with malignant mammary tumors (carcinomas)
include fixation of the tumor itself to the skin or the underlying soft tissue structures, a
rapid increase in size, ill-defined borders, superficial ulcerations, pain, inflammation, and
edema in the area [144]. Inflammatory mammary carcinomas usually present with firm
and painful swelling in the affected gland or mammary chain. In some cases, the adjacent
limb may be affected or cutaneous nodules may be visualized. Regional lymph nodes
may be enlarged upon palpation due to reactive hyperplasia or metastasis of the primary
tumor. These lymph nodes can include the inguinal, axillary, popliteal, internal iliac,
sternal, or prescapular nodes.
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Although mammary cancer can be suspected based on clinical signs and physical
examination findings, histopathology is required for a definitive diagnosis. Biopsy
submission for histopathologic assessment can also aid in determining tumor grade,
stage, and overall prognosis. Surgical biopsies can be submitted during surgical removal
of the mammary tumors, and surgical excision is the treatment of choice in cases of
canine mammary cancer. Lymph node aspiration and cytologic assessment has been
shown to aid in diagnostic accuracy of tumor metastasis, as not all lymph nodes
containing metastatic disease will be enlarged on palpation. Imaging modalities such as
X-ray, ultrasound, CT, or MRI are recommended in detecting metastatic lesions in the
thoracic and abdominal cavities, with CT and MRI being more sensitive options.
Pathophysiology
Approximately 45% of canine mammary tumors are positive for estrogen
receptors. This ratio is 60% in human breast cancer patients. In canine mammary tumors,
exposure to progesterone has been shown to be the main risk factor for hormonedependent development of tumors [145, 146]. Along with changes seen in steroid
hormone receptors like those for estrogen, canine mammary tumor research has also
shown overexpression of specific markers of proliferation, epidermal growth factor,
mutations of the p53 suppressor gene, cyclooxygenases, and metalloproteinases, all of
which share patterns with the human form of cancer. Previous studies have shown that
decreased expression of hormone receptors has a great impact on tumor progression [147,
148] while increased expression of Erb-B2, a specific gene encoding for a member of the
EGF receptor family [149], is directly linked to worsening of malignant disease in breast
cancer [150, 151].
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As a result of tumor development being linked to steroid sex hormones, early
spaying (ovariohysterectomy) in dogs prevents development of mammary tumors
altogether [152, 153]. In dogs spayed (sterilized) before their first estrus occurs, the
probability of mammary tumor development is only 0.05%. These chances increase to as
much as 26% if reproductive alteration is not performed until after the fourth estrus cycle
[154]. In women, early removal of the ovaries (ovariectomy) as well as early pregnancy
resulted in a lower incidence of breast cancer due to the similar effects on estrogen and
progesterone receptor expression [155, 156].
Mammary carcinomas tend to be heterogenous in morphology and biologic
behavior [157], and often have many different components involved, including bone,
cartilage, and fat. Mammary tumors are classified as malignant epithelial tumors, special
type epithelial tumors (SCC, adenosquamous carcinoma, mucinous carcinoma, secretory
carcinoma, spindle cell carcinomas, and inflammatory carcinomas), malignant
mesenchymal tumors, carcinosarcomas, benign tumors, or mixed-type tumor cells [158,
159]. Overall, complex adenomas and benign mixed-type tumors are the histological type
most commonly encountered, while carcinoma forms are the most malignant [159].
Histologic evaluation of tumors based on nuclear differentiation produces three potential
classifications – poor, moderate, and well differentiated. When tumors fall into the ‘less
differentiated’ classification during development, those tumors have the tendency to lose
their receptors for sex hormones like estrogen and progesterone, and tend to form more
aggressive tumors [155]. This phenomenon is shared with human breast cancer, and is yet
another representation of the valuable role dogs play as models for these tumors based on
similar molecular and biological mechanisms.
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An inflammatory subtype of mammary tumors has been identified in both canine
(inflammatory mammary cancer) and humans (inflammatory breast cancer), representing
one of the most aggressive forms [160]. This particular subtype has been shown to be
highly angiogenic and invasive [161], with primary effects on blockage of lymphatic
drainage due to invasion of dermal lymphatic vasculature [161, 162, 163] thereby
resulting in local edema.
Further investigation into classification of mammary tumors includes work
showing increased expression of vimentin, a marker for mesenchymal cells, that is
present in myoepithelial cells [164], in aggressive forms of breast cancer [165, 166].
Metalloproteinases, a common marker of malignancy in human breast cancer, have been
shown to be actively involved in tumor proliferation, angiogenesis, basement membrane
invasion, and metastasis in canine mammary tumors [167]. COX-2, an enzyme involved
in prostaglandin synthesis, has been shown to be overexpressed in both canine and human
mammary tumors [168, 169, 170]. Prostaglandins, lipid mediators, have been linked to
involvement in tumor development and progression. Specific targeting of COX-2 could
provide a means of mammary cancer prevention and treatment development [171]. This
idea is the focus of many current studies, including those on specific mammary tumor
cell lines such as CF33, CF41, CMT9, CMT12, CF35, and CMT28 [172].
Treatment
The most widely used and effective treatment for canine mammary tumors is
surgical resection of the tumor. The type of surgical excision performed (e.g.
nodulectomy/lumpectomy, regional mastectomy, radical mastectomy) depends on the
site, location, and number of tumors that are present. The type of surgery performed has
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not been shown to have an impact on patient survival as long as there are clean margins
on histology. Radical chain mastectomy procedures performed unilaterally have been
shown to decrease the chances of tumor development in remaining mammary tissue. In
previous studies, as much as 58% of dogs that underwent a regional mastectomy
developed a tumor in the mammary gland chain ipsilateral after surgery [144]. Removal
of draining lymph nodes (inguinal lymph node in caudal mammary gland tumors, axillary
lymph node in cranial mammary gland tumors) with submission for histopathologic
analysis in patients where metastasis is suspected is recommended. In the case of
inflammatory mammary tumors, surgery is only viewed as a palliative treatment option,
as these tumor types are considered non-resectable due to their diffuse nature and high
metastatic rates.
Chemotherapy is rarely utilized in dogs with mammary cancer [18], as
chemotherapeutic agents have not been shown to be consistently effective in treatment.
Some studies showed partial responses of mammary tumors to doxorubicin [173, 174].
Analgesics including NSAIDs should be considered for palliative treatment in advanced
stage tumors or inflammatory mammary carcinomas.
Prognosis
Overall, dogs with benign mammary tumors are often cured following complete
surgical excision. Factors that have been shown to have an impact on the prognosis of
dogs with mammary tumors include classification of the histological subtype, biological
grade, degree of invasion, nuclear differentiation, lymphatic involvement, size of the
tumor, and expression of hormone receptors [157, 175, 176, 137]. In terms of tumor size,
tumors with a diameter greater than 3 cm have been reported to have a worse prognosis.
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High grade tumors that are invasive with stromal, lymphatic, or vascular involvement
often have a worse prognosis than low-grade well-differentiated and non-invasive
tumors. Mammary tumor staging consists of stages I through V. Tumors carrying a
higher stage classification include large tumors (II-V), tumors with lymph node
involvement (IV-V), and tumors with metastatic lesions (V). Inflammatory carcinomas
have a grave prognosis [144].
Location of the tumor itself as well as surgical removal technique used or number
of total tumors present do not influence overall prognosis [177, 178]. Assessment of the
tumor via histology alone is not sufficient for accurately determining prognosis, as many
apparently benign tumors may end up metastasizing despite original classification as an
adenoma or mixed-type tumor. Tumors that appear benign biologically may show
histomorphological evidence of malignancy in some cases [179]. The stage and grade of
the tumor also has a big impact on the prognosis [176].
Platelet Background
With the initial observations of platelets dating back to the late 1600s, these blood
‘cells’ have had a long list of names given to them along the way, including globules,
corpuscles, fragments, and even the term ‘besides’ [180] used to describe them. There has
been a lot of controversy as to the proper classification of these 1.5 – 3 μm diameter
[181] megakaryocyte (MK)-derived anucleate cell fragments, regarding whether or not
they are even ‘cells’ at all. Regardless of their classification or the name given to them,
these discoid cells play vital roles in the body, with an ever expanding list of functions
and duties ranging from their well-known roles in blood hemostasis, thrombosis, wound
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healing, and inflammation as well as their more recently recognized interactions with
tumor cells and metastasis [182].
Platelets are produced from polyploidal hematopoietic MKs in the bone marrow
during MK development and maturation [183]. Even though it is known that platelets, in
fact, originate from the MK, the mechanism by which this occurs is still controversial.
Three main models of platelet formation exist: cytoplasmic fragmentation, platelet
budding, and pro-platelet formation [183, 184, 185]. The mechanism in highest current
popularity suggests that MK extend their long branching pro-platelet extensions into the
sinusoidal blood vessels, releasing pro-platelets into the circulation, where further
maturation occurs [183, 186]. This pro-platelet release occurs at the level of the bone
marrow and, most recently discovered, within the pulmonary vasculature [187, 188, 189].
Regardless of the actual mechanism occurring, the end result of platelet
development results in platelets that contain MK-derived cytoplasm complete with
mitochondria, granules, and mRNA. Even though platelets lack a nucleus, and therefore
DNA, they still have the ability to produce proteins courtesy of the multitude of coding
messenger RNA and translational machinery from their parent cell [190, 191, 192, 193,
194]. Platelet and MK production is primarily regulated by the protein thrombopoietin
(TPO) [195, 196], although recent evidence has shown that this process can also be
influenced by interleukin-1 (IL-1) and potentially other interleukin molecules when there
is presence of infection, inflammation, or excessive blood loss [197]. TPO stimulates MK
to increase in their size and ploidy, which thereby stimulates production of proplatelet
processes that later become individual platelets [195]. MK production primarily occurs in
the liver during fetal development in humans, but later occurs primarily at the level of the
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bone marrow in adults. Production of TPO, though, takes place in the liver throughout the
life of humans [198]. Gene expression for TPO production has been illustrated to take
place in various other organs (eg. kidney, bone marrow, lung, spleen, CNS) in humans,
mice, and rats [198, 199, 200, 201, 202]. Recently, Figueiredo et al discovered that dogs
also have the highest level of TPO transcription occurring in the liver, followed by the
bone marrow, spleen, lung, and kidney [203]. In contrast to studies in humans, though,
dogs showed less TPO gene expression in the kidney. This finding is contrary to results
seen in mice and rats, in which the kidney had the highest level of TPO gene expression
[199, 204]. The lung was found to be a potentially important site for TPO expression in
dogs as it had notably higher levels of expression than the kidney, the tissue with the
second highest TPO expression in humans [203].
The proteins found within platelets have three potential sources from which they
originate. These proteins can come from the MK, be taken up by surrounding fluids and
plasma through a sponge-like mechanism (endocytosis), or they can be produced by the
platelet itself through use of a retrotranscription RNA process and splicosome (termed de
novo protein synthesis) [180]. Proteins that have been proven to be synthesized by
platelets include IL-1, tissue factor (TF), plasminogen activator inhibitor-1 (PAI-1),
cyclooxygenase-1 (COX-1), and P-selectin [205, 206, 207, 208, 209]. Most of the
proteins utilized by platelets are stored in granules. Platelet granules consist of three
different types: α-granules, dense granules, and lysosomes. These granules have each
been shown to contain different subpopulations of proteins and other components.
The platelet’s α-granules are the most abundant of these intracellular granules
(approximately 50 to 80 granules per cell in humans) and contain proteins that function
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within the membrane (e.g. αIIbβ3 integrin, P-selectin, CD36), cell adhesion (fibrinogen,
von Willebrand factor (vWf), vitronectin, multimerin I), and coagulation (factors V, IX,
XIII) [210]. More specifically, platelets are now known for their ability to capture and
concentrate molecules involved in the modulation of angiogenesis within distinct
populations of α-granules [211, 212, 213], which will be further discussed later in this
chapter. The exact mechanism by which this heterogenous population of α-granules is
controlled for differential release is not clearly understood yet, but is currently and
actively being studied [214, 215, 216]. Platelet α-granules have also been shown to
contain chemokines which aid in the host response to pathogens due to their antimicrobial properties [217, 218, 219], as well as various pro-inflammatory and
immunomodulatory factors that are involved in inflammation and have been studied with
regards to atherosclerosis [220, 221, 222].
Platelet’s less abundant dense granules (approximately 3-8 per platelet in humans)
contain components including cations (Ca2+), phosphates, and compounds active in
hemostasis (adenosine diphosphate (ADP) and adenosine triphosphate (ATP)) [210]. The
majority of dense granule contents have been found to be non-protein in nature. Platelet
lysosomes are known to play key roles in the endocytic and secretory pathways. Defects
in lysosomes have been linked to pathologies including albinism, immunodeficiency, and
a disease in humans named Hermansky-Pudlak syndrome [223, 224].
A unique and intricate network of channels within the plasma membrane of
platelets, called the open canalicular system (OCS), allows for platelet’s plasma
components to be taken into the cell (endocytosed) or specific granular contents to be
released out of the cell (exocytosed) [216, 225]. Upon activation, platelet granules
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migrate to the cell periphery and bind with the plasma membrane – either utilizing this
OCS to release granular content or by directly exocytosing the contents out into the
extracellular space [216]. Even more recently, this OCS has been shown to potentially
play a vital and important role in the regulation of platelet adhesion [226].
Platelets have been the subject of a multitude of various research studies aimed at
elucidating causes and mechanisms behind many different disease processes in various
different species, ranging from inflammatory conditions, autoimmune diseases, and even
neoplasia. Platelet transcriptomic analysis in humans has been used to demonstrate
differential RNA expression profiles in platelets in several different conditions. Research
by Kondar et al illustrated significant differences between platelets with hyper- and hyporeactive aggregation responses to agonists [227]. They also demonstrated differences
between platelets from patients with essential thrombocythemia and reactive
thrombocytosis compared to those of healthy individuals [228, 229, 230]. Similar studies
also compared platelets from patients with sickle cell anemia or systemic lupus
erythematous [231, 232]. Other applications have been in the identification of mRNA
patterns associated with platelet reactivity, body mass index, and cardiovascular disease
[227, 233, 234], as well as a comprehensive comparison of mouse and human platelet
transcriptomes [235].
Platelets in Hemostasis
Initially noted by early physicians to be located at the site of wounds over 150
years ago, the most well-known function of platelets is their important role in the
cessation of hemorrhage following trauma and/or injury to the vasculature and
surrounding tissues [236, 237]. Under normal physiological conditions, platelets circulate
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the vasculature in a dormant quiescent state due to the presence of healthy intact
endothelium lining the vessel walls. The platelet surface is riddled with various receptors
utilized in hemostasis and adhesion including GPIb-IX-V complex, GPVI, integrins
(αIIbβ3, α2β1, α5β1, α6β1), protease activated receptors (PARs), ADP receptors (P2Y1,
P2Y12, P2YX), thromboxane receptors, platelet endothelial cell adhesion molecule
(PECAM-1), and carcinoembryonic antigen-related cell adhesion molecule (CEACAM1) [238, 239, 240, 241, 242, 243]. Due to their small size, platelets circulate along the
outer edge of the blood stream. This allows detection and fast responses by the platelets
to any vascular damage that may occur [210]. An intact endothelial layer acts as an antiplatelet barrier protecting against any unnecessary thrombosis and through the
endothelium’s release of thrombotic mediators such as nitric oxide (NO) and prostacyclin
[244]. When the endothelium becomes disrupted, platelets are triggered to transform into
an activated state due to the exposure of the subendothelial matrix which results in the
exposure of proteins such as vWf, collagen, fibrinogen, fibronectin, laminin, and
thrombospondin-1 (TSP-1). Once activated, the platelet’s function is dependent on
hundreds of bioactive proteins that are then released [182].
The structure of the platelet itself has the ability to change due to rapid
cytoskeleton remodeling and the presence of an asymmetric plasma membrane. The
internal surface of the plasma membrane is lined with anionic phospholipids such as
phosphatidylserine (PS). In a resting state, the outer surface of the platelet membrane is
covered with neutral phospholipids. Upon activation of the platelet, negatively-charged
PS molecules are flipped to the external surface for roles involved in coagulation [245,
246, 247].
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Upon vessel injury, initial loose platelet tethering to the vessel wall is achieved by
an interaction between platelet GPIb-IX-V complex and vWf in the subendothelial layer
at the site of injury [248, 249]. Following tethering, GPVI and a2β1 interact with exposed
collagen to mediate activation and adhesion of platelets. Formation of a complex between
GPVI and FcR-y leads to an increase in cystolic Ca2+ which may stimulate platelet shape
change, secretion of granules, and activation of additional integrins [248]. Stable collagen
binding is then secured by α2β1 integrin [250, 251] as well as through subsequent
binding of integrin αIIbβ3-vWf, fibronectin, fibrinogen/fibrin, GPVI-collagen, α2β1collagen, α6β1-laminin, and α5β1-fibronectin [252]. The entire process is then amplified
through intracellular fluctuations of Ca2+, stimulating the generation of thromboxane-A2
(TXA2), granule secretion, and further αIIbβ3 activation [189, 253, 254]. Binding of
αIIbβ3 to vWf or fibrinogen allows crosslinking of platelets to occur which ultimately
leads to platelet aggregation and formation of a primary platelet plug (primary
hemostasis) [252, 255].
Following formation of the platelet plug, additional platelets aggregate and trap
other circulating blood cells, thereby contributing to growth of the thrombus. Through
activation of either the intrinsic or extrinsic pathways of the coagulation cascade, a stable
fibrin clot is formed by the actions of thrombin (factor IIa) converting fibrinogen (factor
I) into fibrin (factor Ia) (secondary hemostasis) [256, 257, 258]. Although primarily
derived from hepatic production, thrombin is also partially derived from platelet-derived
prothrombin (factor II) [259]. Platelets are actively involved in the process of
coagulation, in addition to their roles in initiating hemostasis. Flipping of PS onto the
outer surface following platelet activation facilitates the pro-thrombinase complex
35

assembly as well as promotes the generation of thrombin itself [245, 246]. The negatively
charged PS leads to the binding of calcium with subsequent attachment of vitamin K
modified factors. This chain of events ultimately leads to fibrin formation on the primary
platelet plug. Recent studies have also shown that platelets have a role in initiating the
intrinsic pathway of the coagulation cascade by activation of factor XII via dense granule
release of PolyP [260]. Overall, platelets and the coagulation cascade reinforce each other
through a positive feedback loop of activation throughout hemostasis.
Beyond Hemostasis
Beyond the roles platelets play in coagulation and primary plug formation,
platelets are also intimately involved with many other biological events including
recruitment of immune cells, inflammation, wound healing, angiogenesis, and vascular
remodeling.
Immune Function
Platelets are not only innate and inflammatory cells themselves, but they can also
assist, depending on the circumstances, adaptive immunity. They do not only assist
immunity, as has long been known, but have been shown to be active immune cells [180].
One example of this is the evidence provided by Yang et al illustrating the dependency of
expression and amount of P-Selectin found within platelets on plasma fibrinogen levels,
as well as fibrinogen-β3 integrin outside-in signaling [209]. This finding is not only
important in the role of platelets in hemostasis and thrombosis, but also in the interactions
of the platelet with other cells including leukocytes, stem cells, and even tumor cells,
which leads to implications and roles in immune response and tumor growth and
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metastasis [210]. P-selectin is a transmembrane protein that is stored in platelet granule
membranes and, upon activation, translocates to the platelet membrane for roles in
platelet aggregation, interactions between platelets and leukocytes, as well as interactions
between platelets and endothelial cells [261, 262, 263, 264]. These findings have only
been reported in human and/or murine studies. There is very little to no canine specific
research present in the literature with regards to platelet-specific roles in immune
surveillance and function.
Angiogenesis
The formation of new blood vessels from the pre-existing vasculature is termed
angiogenesis. This multistep process involves the sprouting and configuration of new
microvessels [265], and is vitally important in normal physiologic functions including
early fetal development, wound healing, and neovascularization of ischemic tissue [266].
A variety of different cell types have been proven to release angiogenic-regulating
factors, including endothelial cells, stromal cells, leukocytes (neutrophils, macrophages,
natural killer cells), platelets, and tumor cells [267, 268]. Platelet research over the years
has led to the discovery of direct links between platelets and angiogenesis, and more
recent studies have illustrated the ability of the platelet to both potentiate and inhibit
angiogenesis [265]. This suggests that platelets have value as a future target of many
potential therapeutic studies for use in different pathologic diseases including
atherosclerosis [269], rheumatoid arthritis [270], diabetic retinopathy [271], psoriasis
[272], and neoplasia [273]. While most research on the role of platelets in angiogenesis
has taken place in human, rat, and mouse studies, some studies have taken place in
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canines, including those looking specifically at platelet granule localization and contents
[274].
Physiologically, angiogenesis only occurs during times of development (in the
placenta during pregnancy), within the cycling ovary, or during wound healing after acute
vascular complications or trauma [275]. During these times, angiogenesis is active for
days to weeks, and later inhibited. In the case of various disease states such as cancer,
angiogenesis is instead continually activated, a process that is referred to as an
‘angiogenic switch’. This overactive angiogenesis can create a hallmark of various
disease states [267]. Although platelet effects in angiogenesis have been the subject of
many research studies, many of which have contradicted or contrasted others in nature,
the overall and well-accepted opinion is that the activation of platelets has a net
stimulatory effect on angiogenesis [276, 277].
As previously described, platelets have distinct types of intracellular granules (α,
dense, and lysosomes) that have the ability to secrete their contents upon different
external stimuli (platelet activation). Of the multitude of granular contents, various proangiogenic factors, including vascular endothelial growth factor (VEGF), platelet derived
growth factor (PDGF), insulin-like growth factor (IGF), and angiopoietin-1, as well as
antiangiogenic factors such as endostatin, angiostatin, platelet factor 4 (PF4),
thrombospondin-1 (TSP1), and PAI-1, have all been proven to be localized into different
α-granules and preferentially released from the platelet [278, 279]. Additional pro- and
anti-angiogenic factors found in and released from activated platelets are listed in Table
2.1.
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As in human and murine platelets, differential packaging of molecules in αgranules has also discovered for canine platelets by Curotto et al [274]. In this study,
canine platelets were shown to distinctively house vWf and fibrinogen in separate alpha
granules, with very minimal co-localization. This information was in agreeance with
findings in human and mouse platelet studies, suggesting that platelets selectively
package hemostatic proteins in different subsets of alpha granules [214, 280, 281]. Little
is known about the selective packaging and release of canine platelet angiogenic factors,
although research is currently ongoing as the dog progressively reveals itself as a
valuable model for human disease.
VEGF has been described as indispensable to vessel formation in previous
research studies on angiogenesis [277]. More information about VEGF functions is
detailed in the ‘tumor growth & metastasis’ section. One of the angiogenic inhibitors
contained within platelet granules in greatest abundance is thrombospondin (TSP-1),
which has been shown to inhibit the proliferation of endothelial cells, induce apoptosis of
cells [282], and counteract the pro-angiogenic factors released from platelets [283].
Selective release of pro- and anti-angiogenic factors was demonstrated by Ma et al via
their study using human platelets as well as in vitro work with rats which showed that
stimulation of the thrombin receptor, PAR-1, induced platelet release of VEGF while
PAR-4 stimulation caused the release of endostatin, inhibiting VEGF release [211].
Additional research then demonstrated that some angiogenic factors, VEGF and
endostatin, for example, are packaged into separate α-granules, which allows the platelet
to selectively release factors after activation and stimulation [281]. In slight contrast to
this, additional research showed that instead of distinct and separate α-granule
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populations, there was a spatial separation of cargo within each α-granule [284]. Further
studies are needed to elucidate the exact arrangement and organization of these organelles
and their cargo, but the overall function of platelet angiogenic factors and their granule
vessels is clear in their ability to respond and be secreted following platelet activation to
various stimuli and/or disease states. Again, canine specific research mirroring these
findings has not been completed in the literature to our current knowledge, illustrating
gaps in the links between canine and human platelet research.
In addition to platelet granules and their contents, another area of increasing
platelet research is on platelet microparticles (PMPs) or ‘platelet dust’. These platelet
plasma membrane and granule fragments are shed from platelets after activation, and
have been shown to contain a unique set of platelet proteins and lipids. Of all the
microparticles present within the bloodstream, platelet microparticles account for 70-90%
in the healthy human [285, 286]. Involved in many physiologic roles including
hemostasis and coagulation, PMPs have also been associated with many similar disease
states previously mentioned including atherosclerosis, rheumatoid arthritis, and cancer
[287]. PMPs have the ability to promote endothelial survival, proliferation, migration,
and tube formation due to their contents including, but not limited to, VEGF and bFGF
[288]. Additional studies have demonstrated that PMPs could induce angiogenesis after
thrombin activation [289]. Platelet microparticle research for canines is limited, but has
been initiated through studies looking at collection techniques and their effects on the
thrombin generating ability of PMPs [290], although detailed effects in different disease
processes in canines have not been studied in depth to date.
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Tumor Growth and Metastasis
Platelets play a significant role in tumor progression by influencing angiogenesis,
immune evasion, and metastasis [291]. Bi-directional signaling between platelets and
tumor cells affects the tumor microenvironment and impacts angiogenic and metastatic
potential. Under normal circumstances in the healthy body, angiogenesis is overall
dormant, with only 0.01% of endothelial cells dividing [275], along with tight regulation
during times of activity. In pathologic cases such as cancers that involve active
angiogenesis, a specific angiogenic ‘switch’ takes place allowing excessive vascular
proliferation with the involvement and participation of platelets. Angiogenesis has been
implicated to have involvement in over 70 disease conditions [275]. Of particular note is
the discovery of the involvement of platelets and angiogenesis in tumor regulation, a
theory which was first proposed over 50 years ago [292]. Several studies have established
that platelets play an important role in both angiogenesis within primary tumors and
tumor capacity for metastasis mediated by specific adhesion molecules. There is
additional evidence supporting the role of the platelet releaseate favoring either the proor anti-angiogenic state [293, 294].
Tumors can actively sustain their survival at a size less than 3 mm diameter
through simple diffusion of essential oxygen and nutrients [292]. After this point, the
tumor cells require additional sources of nutrient and oxygen delivery, therefore requiring
an independent blood supply. The vascular network established within tumors allows the
malignant cells to escape from the primary tumor, enter circulation, and metastasize to
distant locations in the body, making angiogenesis an important component of
tumorigenesis. Since the link between platelets and angiogenesis was proposed near the
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most recent turn of the century, research into the links between platelets, angiogenesis,
and tumors has boomed for all species, especially those regarding animal models.
Tumor vasculature, in general, is abnormal and aberrant when compared to
normally developed and maintained vasculature of the body. Tumor microvessels are
heterogenous in nature with uneven diameters, hemodynamic upsets, increased
permeability to large molecules, and disrupted endothelial linings [295, 296]. Studies
have shown that the stabilizing effects of platelets on the tumor microvasculature are very
likely dependent on the release of platelet factors after activation, although the exact
mechanisms and factors critically involved have not been identified [297]. In studies
where platelets were depleted, hemorrhaging occurred within the tumor stroma,
suggesting that these platelet factors involved play a role in counteracting the damage
caused by immune cells that migrate into the stroma [297].
The ability of platelets to play a role in ‘hiding’ or ‘cloaking’ tumor cells
circulating in the vasculature is well documented in the literature. This function provides
a way for tumor cells (that would normally be a target for immune cells) to evade
detection and killing by immune cells such as NK cells, both through physically shielding
the tumor cells from detection as well as through factors released from platelets [298,
299]. One example of this is platelet released TGF-β following interaction with tumor
cells, which results in suppressed NK cell receptor activation [300]. Tumor cells have
been shown to induce platelet aggregation, a response termed ‘tumor cell induced platelet
aggregation’ (TCIPA), in which some tumor cells express platelet integrins (α2β1, αIIbβ3)
to enhance metastasis [301, 302, 303]. The in vivo relevance of this intricate network is
evident, as the metastatic potential of a tumor has been demonstrated to correlate with its
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ability to aggregate platelets [304]. Other platelet-derived factors that have been shown to
have key roles in tumor metastasis following gene-depletion studies include GPIbα,
GPVI, P-selectin, and α2bβ3 [305, 306, 307, 294]. Thrombocytopenia, anti-platelet
treatment, or blockage of specific platelet adhesion proteins with antibodies against Pselectin, GPIb-IX, or GPIIb-IIIa have all been shown to negatively impact tumor
progression [308, 309, 310, 311].
Although most focus on platelet-tumor interactions have been on the effects of
factors contained and released from platelet α-granules, recent research has shown that
dense granule components, notably ADP and ATP, can aid tumor metastasis via
disruption of the assembly of endothelial intracellular junctions. This aids metastasis in
the ability for tumor cells to extravasate from the vasculature into the subendothelial
space. By the mediating the effects of ADP and ATP on P2Y2 receptors, new targets for
therapies targeting tumor metastasis now exist that may not interfere directly with platelet
function [312]. The α-granule factors mentioned above (VEGF, PDGF, TGF-β) have also
been shown to play roles in altering the integrity of endothelial junctions. In addition to
molecules that control angiogenesis, activated platelets release factors that modulate
hemostasis, inflammation, and cell proliferation. These processes are all necessary for the
switch from dormancy to progression to take place. The injection of tumor cells that were
previously incubated with washed platelets resulted in an increase of pulmonary
metastasis in mice. This indicates a role of tumor cell priming by platelets for metastasis
to take place [301]. Similarly, exposing tumor cells to PMPs also resulted in an increased
metastatic potential, as shown in other studies [313]. Platelets also have a role in
‘priming’ future sites of metastasis, as evidenced by studies looking at bone tumors. This
43

pre-metastatic method of communication between platelets and distant sites (bone in this
particular study) was made possible through the sequestering of tumor-derived proteins
by the platelets [314]. This suggests a more complex role of platelets in metastasis of
tumors beyond direct interactions and effects.
In general, thrombocytosis is a condition that is often observed in patients with
cancer. When present, this elevation in platelet number is usually associated with an
advanced stage of disease and a poor prognosis [315, 316]. In many cases, human cancer
patient platelet α-granules contain elevated amounts of VEGF and angiopoietin as well as
decreased levels of TSP-1 [317, 318, 319]. Various therapies have been tested and
implemented targeting platelet function and/or angiogenic molecule blockade throughout
the years, since as early as the 1970s [292]. One of the most well studied angiogenic
targets for therapy development has been the VEGF signaling pathway. VEGF is a key
player in both early and late angiogenesis, and has been shown to be produced by tumor
cells and stroma, and its receptors are found on tumor cells and stroma as well [320].
VEGF has been linked to poor prognosis in human cancers including colon cancers,
breast cancers, gastric carcinomas, prostrate cancers, lung cancers, various sarcomas, as
well as melanoma [320], and has therefore been the target of current anti-angiogenic
therapeutics. Specific platelet function blockade through therapies including aspirin has
been shown to have positive effects on increasing survival and decreased recurrence in
some studies [321, 322], although additional research is needed to identify more effective
therapies and therapeutic targets as results have been somewhat beneficial but overall
inconsistent across species, type of neoplasia, and stage of disease.
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Of the thousands of molecules thought to play a role in angiogenesis and/or tumor
progression, about one hundred have entered human clinical testing for their roles in antiangiogenic therapy. Of these, only approximately ten have been approved for clinical use
[323]. The first to be FDA approved was the anti-VEGF antibody therapeutic
bevacizumab (Avastin), which was shown to improve the survival of human patients with
colorectal cancer, non-small cell lung cancer, breast cancer, glioblastoma, and renal cell
carcinoma [324, 325, 326, 327, 328]. While many studies and trials utilizing these antiangiogenic therapies have shown reduced tumor growth, recent studies have suggested
that these therapeutic approaches may actually select for a more invasive phenotype in
the end [329, 330]. This occurrence can potentially be attributed to the development of an
adaptive/evasive resistant population of tumor cells to anti-angiogenic therapies due to
selection for more aggressive cells capable of surviving [331]. This theory of therapy
resistance is seen with various disease processes in medicine, including antibioticresistant strains of bacteria and resistant populations of parasites in veterinary medicine.
As detailed above, future integration and use of canine models for various human cancers
will aid the progression of research into therapies through increasing efficient translation
from the bench top to clinical use.
In the case of canine tumors and their interactions with platelets, studies are
limited. Interestingly, in a recent study by Bulla et al, canine platelets and their molecular
contents were shown to actually inhibit the migration of three canine OSA cell lines
(OSA-8, OSA-40, OSA-78) in vitro [332]. In addition, effects of platelets on tumor cell
migration varied between different cell lines, suggesting that variation among different
tumor cell lines can effect the magnitude of platelet effects that take place. Overall, these
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findings contrast similar studies in humans and other species, that have shown platelets to
have a prometastatic effect on tumor cell lines. For those studies, though, the tumor cell
lines have mostly consisted of epithelial cancers (eg. carcinomas, adenocarcinomas) [301,
312, 333], which contrasts to the OSA cells lines in this canine study. There is very little
evidence of the effects of platelets on the migratory or metastatic effects of mesenchymal
tumors. One study in mice illustrated that induction of thrombocytopenia resulted in a
decrease in pulmonary metastasis in fibrosarcoma, which fits with platelets having
positive effects on tumor growth and metastasis [334]. Further investigation by Bulla et al
revealed a downregulation of epithelial-mesenchymal transition (EMT)-related genes in
the canine OSA study, which could explain the inhibitory effects observed [332].
Wound Healing
Through the formation of a platelet plug and later a blood clot during hemostasis,
platelets also provide a scaffold system by which wound healing can take place [335].
Initially, the release of various platelet cytokines and growth factors (greater than 60
substances active in wound healing) at the site of a wound elicits influx of inflammatory
cells as well as endothelial cells and fibroblasts [336, 337, 338]. Subsequently, relaxation
of the vascular smooth muscle and vasodilation occurs as a result of the calcium
mobilization and production of NO after binding of VEGF [339], which aids in the
delivery of blood flow to the wound. While later stages of wound healing (proliferative
and remodeling phases) take place without direct platelet interaction, studies have shown
the vital role that platelet secreted factors play in allowing these complex events to take
place [338].
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Modern therapies now include the use of platelet-rich plasma (PRP) gel
placement in wounds to promote proper healing. Examples of PRP use in wound healing
therapy in humans include diabetic digit ulcerations, orthopedic surgical procedures,
muscle and tendon repair, ophthalmic procedures, and cardiac surgeries [340, 341, 342,
343]. In veterinary medicine, PRP has been studied for use in various wound healing
circumstances. For example, recent work from Canapp et al revealed significant
improvement in dogs with partial cruciate ligament tears after intra-articular injections of
PRP [344]. In horses, PRP and platelet concentrates have been used in the treatment and
enhanced healing of various tendon and ligament injuries for many years [345, 346, 347].
Platelet Purification
Due to the small amount of protein and RNA present in a platelet relative to their
nucleated counterparts, appropriate sample collection and preparation is key for obtaining
reliable results in proteomic or transcriptomics analyses of platelets. [348, 349].
Significant challenges arise when working with platelet protein and mRNA, as samples
are easily contaminated by proteins and RNA derived from other blood cells in much
higher proportion including, most notably, leukocytes. In human platelet studies, platelets
have been shown to contain 65-fold less protein and 12,500-fold less mRNA when
compared to leukocytes [350, 351]. Exact numbers comparable to this study are not
available for the canine species, although the proportions are likely similar. Regardless of
species, it is essential to develop platelet isolation techniques and to characterize the
purity of these samples, not only on the basis of cell count, but also by volume and
protein and mRNA content, to ensure a pure and valid representation of the platelet
component being studied. Additionally, clinical samples obtained for use in platelet
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research tend to be of low total volume. Due to this, sample purification techniques must
produce high yields when performing proteomic and transcriptomic studies for the use in
biomarker discovery and identification.
Throughout the years, platelet purification techniques have greatly evolved. In
human medicine, platelet purification technology has evolved via the use of platelet
apheresis. With this technique, platelets are directly collected from a patient while other
blood components are replaced back into the body during collection. This allows large
platelet samples to be collected from a single patient, but the drawback is the need for
expensive and specific equipment to accomplish this methodology. Alternatively, human
medicine relies on platelet pooling from whole blood utilizing large volumes of blood
collected from multiple patients. Specialized filters and centrifugation techniques are
used to ensure highly pure platelet yields. The downside of these techniques, though, is
that platelet losses are high. In veterinary research and medicine, smaller patient size and
lack of sophisticated and expensive equipment greatly limits the volume of blood and
platelet samples that can be obtained from each patient.
In addition to issues with total platelet volume and purity, the platelet proteome,
and even transcriptome, can be greatly altered by the activation of platelets within the
sample. Great care must be taken in the techniques used to collect and isolate platelets to
prevent platelet activation during sample collection and also minimize sample handling
and prevent activation in vitro. The volume of the sample obtained, the target sample
purity to be reached, and the potential for platelet activation ultimately determine the
techniques that can be successfully be used to obtain a reliable and representative platelet
sample suitable for proteomic and/or transcriptomic studies in all species.
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Proteomics
Background
Proteins, made up of amino acids, are the building blocks of all living organisms.
Proteins can vary greatly in their structure and function and are the product of the genes
encoding them. While many species’ genomic sequences have been described, many
limitations in genomics exists with regard to understanding the underlying function and
implications of each gene. A ‘proteome’ is the total set of the protein products resulting
from the protein-coding genes within a particular cell type or the genome of an entire
organism. The study of ‘proteomics’ involves analysis of the entire protein composition
of a particular cell or an entire organism [352]. Using proteomics, the structure,
interactions, and functions of proteins can be understood along with the biological
mechanisms they are involved in within cells and tissues including those in different
diseased states as compared to normal states. Ultimately, the information gathered from
proteomic studies can be applied to the development of biomarkers of diseases, including
cancer, to aid scientists as well as clinicians in early disease detection, disease
pathogenesis, and development of novel therapeutic modalities [353].
Protein numbers far exceed the number of protein-coding genes. The human
genome contains greater than 30,000 genes. From these genes, as many as 100,000
proteins could result. This discovery led to a shift in the focus of research from that of
single gene or protein studies to more broad based studies looking at entire protein sets
within a cell or organism. Aside from not only providing protein identification, mass
spectrometry-based approaches like proteomics can elucidate all of the various aspects of
protein functions and interaction within a cell including different modifications made to
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proteins, their isoforms, and their interactions with different proteins and involvement in
biological pathways [355]. The development and utilization of proteomics provides a
valuable tool to expose the links between cells and disease processes at the level of the
protein. This information cannot be obtained through genetic studies or through looking
at RNA, as poor correlation exists between those molecules and their corresponding
protein levels as, for example, many mRNA are non-coding and/or undergo alternative
splicing [356].
An important initial step in proteomics is to separate out proteins within the
sample itself to decrease its complexity. Multiple methodologies have evolved over time
beginning with the SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel
electrophoresis) and later 2-DE (two-dimensional gel electrophoresis), the latter of which
is the most commonly used gel-based technique today. In these electrophoretic
methodologies, currently the most commonly used method for protein separation,
samples are denatured and separated based on their isoelectric points as well as their
molecular weights. Stained protein spots within the gel are removed and digested into
fragments for analysis via mass spectrometry [357].
Mass spectrometry allows extremely high sensitivity and specificity when
identifying, characterizing, and quantifying proteins present in a sample. Variations in
techniques (e.g. top-down and bottom-up approaches) may or may not involve the use of
a protein digestion step for the generation of peptides. For bottom-up proteomic studies
following protein digestion, peptides are ionized (via electrospray ionization or matrixassisted laser desorption ionization) and passed through a mass analyzer for
determination of their mass-to-charge ratio (m/z). Five different mass analyzers may be
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used in proteomics including the time-of-flight (TOF), the ion trap (IT), the quadrupole
(Q), the Fourrier transform-ion cyclotron (FT-ICR), and the Orbitrap. The MS spectra is
then used to identify proteins by a number of bioinformatic methods that rely on database
searching for the species of interest. Various different areas of research in proteomics
utilize mass spectrometry, including those looking at protein-protein interactions, posttranslational modifications, structural proteomics, quantification or modifications of
proteins, and those with protein identification [358].
One limitation and obstacle faced when performing proteomic studies was the
loss of many large, basic, or hydrophobic proteins when utilizing 2-DE gel separation of
proteins. This problem has been addressed in the years following by creation and
utilization of various gel-free methods. Some of these novel gel-free techniques include
COFRADIC (combined fractional diagonal chromatography) [359] and MudPIT
(multidimensional protein identification technology) [360]. Combining several different
proteomic techniques has proven to provide the greatest collection of protein data overall
[361, 362].
Additional analysis of protein data can be completed through the use of a
quantitative step. Quantitative analysis of a proteome is an efficient study comparing two
or more conditions that may have different phenotypes or environments, also known as
expression proteomics. With these quantitative analyses, one main focus is on
identification of differentially expressed proteins between samples, highlighting those
abundant in various disease states, such as those abundant in cancer tissues. The
differentially expressed proteins can then be used as biomarkers in diagnosis and
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determining the prognosis. These can be performed via gel or gel-free methodologies
(using the mass spectrometer) as well.
Proteomics and Cancer
Cancer is a disease that is multifactorial in nature, and is the result of
dysregulation of cellular functions and signaling used to normally control cell behavior,
including proliferation and apoptosis. These changes in function are due to mutations and
alterations at the genetic, genomic, and/or epigenetic level of the cell [362]. Proteins are
the key players in directing the proliferation and advancement of cancers from survival of
tumor cells themselves, growth of tumors in size, invasion of the vasculature and
neighboring tissues, metastasis at distant locations in the body, and the response formed
to the therapies administered [364]. Revealing and understanding these protein-fueled
pathways and biological mechanisms will help researchers and clinicians understand
cancer development, progression, metastasis, and ultimately ways by which cancer can be
detected earlier and treated efficiently.
Proteomics is a highly efficient and accurate technique that is used for identifying
changes in protein patterns in many diseases, including cancers [365]. Use of proteomics
in different cancer studies allows the creation of tumor-specific profiles to be created on
the protein level. This will then allow the detection of a multitude of novel tumor specific
biomarkers and allow more accurate prognostic predictions to be made. Various studies
have examined the different cancer cell proteomes in recent years. One example of this is
with Yang et al in their efforts at gastric cancer biomarker identification [366]. Including
other similar studies, comparative proteomes conducted on gastric cancer samples
identified more than five protein differences (eg. SLC3A2, MET proto-oncogene receptor
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tyrosine kinase, ephrin type A receptor 2, fibroblast growth factor receptor 2, integrin
beta 4) for potential future use as biomarkers [367].
Aside from detection and prognosis, though, protein mapping will allow detailed
insight into the tumor-specific pathogenesis for each type of cancer [368], as well as the
potential to offer individual-based assessments. Until recently, proteomics use in canine
cancer research has been greatly limited. Slow advancements in interest and progress has
been initiated, though, as more and more evidence linking canine cancer to similarities in
human cancer through their benefits to medicine as animal models has been shown.
While limited in case numbers, proteomic profiling has been utilized in analyzing gene
expression as well as differentially expressed proteins in some comparative studies on
various tumor types (lymphoma, mammary tumors, prostatic tumors, mast cell tumors)
[369, 370, 371, 372, 373, 374, 375]. Initial steps have been made in utilizing genomic and
proteomic analyses in identification of key gene and protein changes that could later lead
to use in diagnostics [376].
Platelet Proteomics
The proteome of a cell can be highly dynamic and offers unprecedented
opportunities to unlock the mystery of biologic processes and to discover new diagnostics
and therapeutics for human diseases. This is particularly true for platelets, which are
readily available and have a limited repertoire of proteins, and where the proteome is
largely independent of changes in gene expression [377].
The most important step of proteomic analysis, especially in the case of platelets,
is preparation of the sample to be studied. Electrophoresis, liquid chromatography, and
mass spectrometry are all extremely sensitive to sample contamination. In the study of
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the platelet proteome, other blood cells are the main source of contamination concern.
Platelet isolation methodologies must be sure not to alter the structure or function of the
platelets themselves, as well as make sure to eliminate all or most other blood cells and
their proteins from the samples to be analyzed in order to obtain a proteomic profile
representative of the platelet itself. Some of these important factors to be considered
include the use of drugs that alter platelet function (aspirin, non-steroidal antiinflammatories), vessel trauma during venipuncture, rapid platelet isolation techniques,
temperature of platelet sample storage, and length of platelet sample storage before use
[378, 379, 380]. Efforts are made to prevent iatrogenic platelet activation and/or lysis.
Platelet samples are ideally collected using citrate-containing anticoagulants and stored at
room temperature or 37C. Some of the very first studies of the platelet proteome utilized
2-DE gel in 1979 [381]. The first platelet proteome analysis with mass spectrometry was
performed in 2000 by Marcus et al using MALDI-TOF after 2-DE was performed [382].
Nearly 190 proteins were identified in their study.
As previously mentioned, the platelet, albeit small in size and without a nucleus,
is complex in the packaging and volume contained within its intracellular granules
(alpha, dense, lysosomes). One of the most important functions of platelets following
their aggregation is the release of their granule contents. Previous studies consisting of
proteomic analysis of platelets in rats bearing actively growing tumors revealed that
levels of VEGF, bFGF and PGDF tended to be higher and the levels of the angiogenesis
inhibitor endostatin tended to be lower. This proportion was persistent throughout the
experiment (120 days) and reflects a pro-angiogenic tumor environment [383].
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Platelet granules - their contents of particular known interest for various roles in
hemostasis, wound healing, inflammation, and even cancer – have also been the subject
of component-specific proteome studies by isolation of granules themselves. Special
attention must be paid to fraction purity when studying particular cell organelles as
contamination from neighboring organelles (eg. mitochondria) can greatly skew results.
Steps including sucrose gradients followed by validation methods such as electron
microscopy and Western blot assays allow isolation of platelet alpha granules for use in
proteomic studies [259]. Dense granules present greater difficulty to study due to their
low abundance (only 3-9 per platelet approx.) and high amounts of non-protein
components. Studies have been successful, though, such as those by Hernandez-Ruiz et
al, which identified roughly 40 dense granule proteins after validation using electron
microscopy and Western blot [384]. Limited studies have been conducted on platelet
lysosome proteomics, although their importance in diseases such as Hermansky-Pudlak
syndrome suggest a valuable use for these studies in the future [224].
Proteomic studies of platelets extend beyond those conducted on the entire cell.
Specific platelet compartments have been studied by the use of various platelet agonists.
Among various platelet agonists, thrombin is one of the most important and most
efficient agonists in triggering platelet activation and subsequent granule release [385].
Specific protease-activated receptors (PAR-1 and PAR-4) are required for this activation
process to take place along with GPIba [286]. Agonists like thrombin have been utilized
in various studies looking at activation cascades at the protein level. Maguire et al
performed studies on the platelet phosphoproteome after thrombin activation, overall
detecting 67 phosphorylated protein spots on 2-DE gel [387]. Another study used
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thrombin to activate platelets to study the platelet releaseate proteome in atherosclerosis,
identifying more than 300 proteins overall using MudPIT, with 51 of them having no
previous evidence of being found in platelet secretion [388]. Platelet agonists can also be
used to compare proteins involved in platelet signaling pathways. Garcia et al used
thrombin receptor-activating peptide (TRAP), a molecule that promotes platelet
secretion, to compare PAR-1 signaling proteomes between activated and resting platelets
[389]. Other studies such as those by Senis et al have been used to explore the signaling
pathway of alphaIIb-beta3, utilizing fibrinogen activation of platelets to identify 27
proteins involved [390].
Platelet membrane proteins, important factors involved in platelet activation,
adhesion, and metabolism, are often underrepresented in many proteomic studies due to
their low numbers, heterogenous structure, and hydrophobicity [391]. These properties
make them difficult to use in many of the steps involved in proteomics, including
electrophoresis, protein digestion, and MS analysis. Due to these limitations,
modifications and novel techniques have been utilized to allow more accurate studies to
be conducted on platelet membrane proteins. Moebius et al was the first study conducted
on MS analysis of the platelet membrane. Membrane fractions were prepared with
additional cleaning steps along with specific hydrophobic extraction steps within the
protocol [392]. Protein separation was conducted using a 16-BAC/SDS PAGE technique
which allows greater resolution of membrane protein separation as compared to
traditionally used SDS methods. Overall, an increase in membrane protein products of
six-fold was obtained. Other studies have utilized glycosylation trapping techniques to
isolate and enrich membrane protein products, since most surface and secreted proteins
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are glycosylated [393]. More recently, Lewandrowski et al identified over 1,200
membrane proteins by combining SDS-PAGE, MudPIT, and COFRADIC [394].
Platelet proteomics involving either the entire cell or their sub-cellular
compartments is a valuable method to be used in studying a wide variety of diseases
using descriptive, comparative, and quantitative analyses. Insight into the roles platelets
play in the pathogenesis of various diseases, cellular signaling, and biologic mechanisms
will greatly impact the development of future diagnostics as well as treatment modalities
and modes of evaluative treatment responses in all patients, both human and animal.
Summary
Growing evidence has linked platelets to critical roles in cancer survival,
pathogenesis, and metastasis, and has pioneered the development of novel treatment
strategies and targets. The dog has proven to be an extremely valuable model for human
diseases, most notably for various forms of naturally occurring cancers shared with their
human counterparts. Through investigations into ways to efficiently and accurately
evaluate canine platelets along with their roles in various cancers that affect dogs as well
as humans, progress can be made in understanding complex biologic signaling pathways
and chemical mechanisms as well as molecular targets identified for use in developing
specific chemotherapeutic agents.
Platelets’ roles in the development, survival, proliferation, and metastasis of
cancer through growth factor secretion, angiogenesis, and escape from immune
surveillance are primarily governed through the actions of proteins involved in all of
those processes. The recent advances in mass spectrometry and the study of proteomics
has allowed deepening exploration of the hundreds, and now thousands, of proteins
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present in platelets and their functions throughout various platelet functions and cellular
interactions, including those of disease states like cancer. The surface has just been
scratched on determining details behind platelet roles in cancer, especially those in
valuable animal models such as the canine, providing an open landscape for future
discovery, mechanism understanding, and therapeutic development.

Table 2.1

List of angiogenic factors within platelet granules
Pro-angiogenic Factors

Anti-angiogenic Factors

Vascular endothelial growth factor (VEGF)

Endostatin

Platelet derived growth factor (PDGF)

Angiostatin

Insulin-like growth factor (IGF)

Platelet factor 4 (PF4)

Angiopoietin-1

Thrombospondin 1 (TSP1)

Matrix metalloproteinases (MMP) 1, 2, 9

Plasminogen activator inhibitor 1 (PAI1)

Interleukin 8 (IL8)

Tissue inhibitor metalloproteinases (TIMPS)

Epidermal growth factor (EGF)

CXCL4L1 (non-allelic variant of PF4)

Basic fibroblast growth factor (bFGF)
Stromal cell derived factor (SDF) 1
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ULTRA-PURE PLATELET ISOLATION FROM CANINE WHOLE BLOOD
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Abstract
Background
Several research applications involving platelets, such as proteomic and
transcriptomic analysis, require samples with very low numbers of contaminating
leukocytes, which have considerably higher RNA and protein content than platelets. We
sought to develop a platelet purification protocol that would minimize contamination,
involve minimal centrifugation steps, and yield highly pure platelet samples derived from
low volume whole blood samples from healthy dogs.
Results
Using an optimized OptiPrep density gradient technique, platelet recovery was
51.56% with 99.99% platelet purity and leukocyte contamination of 100 leukocytes per
108 platelets, on average. Platelet samples were subjected to additional purification with
CD45-labeled Dynabeads after density barrier centrifugation resulting in a 95-fold
depletion of residual leukocytes. Platelets purified using these methods remained
inactivated as assessed by Annexin V and P-selectin labeling with flow cytometry.
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Conclusions
The use of OptiPrep density gradient is a quick method for obtaining highly
purified platelet samples from low volumes of canine whole blood with minimal
contamination. Additional depletion of residual leukocytes can be achieved using CD45labeled beads. These platelet samples can then be used for many downstream applications
that require ultra-pure platelet samples such as RNA and protein analysis.
Background
Platelets are known to play important roles in hemostasis and tissue repair.
Recently, the role of platelets in angiogenesis is being evaluated more closely as a
potential modulator of tumor progression and metastasis. However, the continued
exploration of platelets and their roles in hemostasis, healing, or cancer progression and
metastasis requires increasingly pure platelet isolates.
Newer methods being employed in the study of disease include proteomic,
transcriptomic and metabolic studies that require platelet samples with very low levels of
leukocyte contamination. Leukocytes have been estimated to contain 12,500-fold more
mRNA and 65-fold more protein than platelets [1,2]. Therefore, even very low numbers
of contaminating cells will produce significant contamination. Current commonly used
methods for producing platelet rich plasma (PRP) can yield up to 72% platelet recovery
but, in exchange for the high platelet yield, these samples often have high residual
leukocyte counts (> 3,000 leukocytes per 108 platelet) [3,4]. High levels of leukocyte
contamination would produce a sample in which the majority of isolated mRNA is likely
to be of leukocyte, rather than platelet, origin.
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Methodologies that have successfully been used to produce highly pure platelet
isolates devoid of notable leukocyte contamination require relatively large volumes of
whole blood (40mL or greater) to recover sufficient platelets for study as a significant
percentage of the platelets are lost during the purification process [5]. High platelet
purities may also be achieved by use of platelet aphaeresis during blood collection as well
as use of specialized leukocyte filters. Specialized equipment and training are required
for platelet apheresis collection methods, which are not widely available in the clinical
veterinary practice setting [3,6]. Again, employing multiple filters for leukocyte depletion
from platelet samples leads to considerable platelet loss, often requiring large volumes of
whole blood or platelet concentrate [7]. The larger blood volumes required for these
techniques also makes them impractical for use in preparing clinical veterinary samples
for analysis. Other techniques for producing highly pure platelet samples often require
multiple centrifugation steps. The physical stress of these centrifugation steps often leads
to platelet activation and subsequent granule content release which alters results if
looking at platelet contents via protein or RNA.
The dog has quickly gained recognition as an import- ant animal model for many
human diseases including cancer. Not only are dogs of veterinary importance from a
companion animal standpoint, but also develop many of the same naturally occurring
cancers and diseases as humans [8-10]. Our goal was to provide a fast and reliable
method for producing ultra-pure platelet samples suitable for proteomic and
transcriptomic analysis from clinically relevant (3–5mL) whole blood volumes with
minimal platelet activation.
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Results
Decreased leukocyte contamination using OptiPrep density barrier
Following centrifugation of whole blood with a 1.063g/mL density barrier,
distinct layering was observed (Figure 1). After optimization of the OptiPrep density
barrier centrifugation and platelet layer extraction steps, collection of 1 mL of the cloudy
second layer consistently yielded a highly concentrated platelet fraction with an average
purity of 99.99 ± 0.01% (mean ± standard deviation) by manual count, and average
platelet recovery of 51.56 ± 9.66%. These platelet fractions were highly pure with only
100.07 ± 48.77 leukocytes per 108 platelets. The original whole blood samples had cell
counts, on average, of 2,457,405 ± 746,380 leukocytes per 108 platelets. Therefore, on
average, optimized density barrier centrifugation resulted in a 24,574-fold decrease of the
leukocyte to platelet ratio from whole blood.
Reduction of leukocyte contamination by bead separation
Throughout optimization of the OptiPrep density barrier purification technique,
CD45-labeled Dynabeads were tested as a method to remove additional residual
leukocytes. An average 95-fold decrease in leukocyte contamination was seen for
samples containing high levels of contaminating cells. In samples containing an already
low amount of contaminating leukocytes such as those seen with the OptiPrep density
barrier centrifugation, there was no added benefit of continuing with the additional
purification step using the leukocyte-specific beads due to additional platelet loss from
the bead separation process.
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Purity, contamination, and assessment of activation by flow cytometry
Flow cytometric analysis of the platelet samples obtained after OptiPrep density
barrier centrifugation indicated, on average, 99.47 ± 0.21% CD61-positive events and
0.19 ± 0.04% CD45-positive events. After incubation with CD45-labeled Dynabeads the
samples had, on average, 98.84 ± 0.03% CD61-positive events and 0.27 ± 0.03% CD45positive events (Figures 2 and 3). Platelet sample activation was evaluated using Annexin
V and P-selectin labeling by flow cytometry (Figures 4 and 5). After initial centrifugation
with the 1.063g/mL density barrier, the platelet sample had 0.66% annexin positivity and
0.4% P-selectin positivity, and after incubation with CD45-labeled beads there was
3.00% Annexin positivity. Because of the platelet function inhibitory effect of the PECT
anticoagulant, whole blood was collected in citrate to acquire PRP for use as positive
controls by activating with thrombin and collagen. Thrombin activated platelets had
25.18% Annexin positivity and 13.44% P-selectin positivity while platelets activated by
collagen had 88.28% Annexin positivity and 0.66% P-selectin positivity.
Discussion
The described technique allows the purification of canine platelets using density
barrier centrifugation and yields a highly pure platelet sample with very low leukocyte
contamination (99.99±0.01% platelet purity with only 100 leukocytes per 108 platelets).
This technique leaves platelets in a resting, non-activated state as assessed with Annexin
V and P-selectin labeling by flow cytometry. Minimal centrifugation steps and sample
handling is involved along with no additional need for filtering or special aphaeresis
equipment. Moreover, this procedure is quick and efficient, resulting in a platelet
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recovery of approximately 52%, and can be performed on small, clinically practical
whole blood sample volumes (3–5mL).
Cell counting should be performed following the density barrier centrifugation
step, and if residual leukocytes are seen in the counting chamber, it is recommended that
the sample be incubated with CD45-labeled Dynabeads for removal of residual
leukocytes to increase the purity of the platelet sample. Our results show that with this
procedure residual leukocytes can be further reduced 95-fold (up to 586-fold maximum
observed with optimized protocol) with minimal platelet loss.
During our optimization trials, we determined that the volumes and the ratio of
whole blood to OptiPrep density barrier should be carefully maintained. Adding more or
less than 3mL of blood on top of the 5mL of density barrier can cause poor layer
separation, resulting in lower platelet purity and recovery. It is also vitally important to
handle samples with care as to avoid any disturbance or mixing of the post-centrifugation
layers, which may re-contaminate the platelet layer.
Little comparable data exists in the current literature in regards to veterinary
species, including the dog. In humans however, density gradient centrifugation methods
for platelet purification are well established, but are aided by aphaeresis-derived platelet
concentrates obtained from large whole blood volumes [2,11,12]. One example of human
platelet purification is the 1990 study from Ford et al. which used a 1.063g/mL OptiPrep
density barrier centrifugation of human whole blood to achieve a platelet recovery of
70% with 125 leukocytes per 108 platelets [12]. More recently, Birschmann et al.
achieved platelet samples with 21.9 and 1.5 leukocytes per 108 platelets using prepurified PRP and apheresis- derived platelet concentrates over layered OptiPrep density
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barriers, respectively [2]. In clinical veterinary settings, the collection of large blood
volumes from single clinical patients is neither safe nor ethical and aphaeresis equipment
is neither easily accessible nor cost effective. Here we describe a platelet purification
technique that uses low clinically relevant volumes of canine whole blood and yields
ultra-pure non-activated platelets with minimal leukocyte contamination.
Conclusion
This study details an efficient technique for purification of canine blood platelets
that results in ultra-pure resting platelet samples derived from small, clinically reasonable
whole blood volumes. These ultra-pure resting platelet samples are thus suitable for use
in multiple downstream analyses including proteomic and transcriptomic methodologies
for the study of platelet physiology and functional roles in naturally occurring diseases in
dogs.
Methods
Platelet purification
Healthy female intact Walker hound dogs were used in this study. The dogs were
not exposed to any medications or vaccines for at least two months before initiation of
the study. Animal use was approved by the Mississippi State University Institutional
Animal Care and Use Committee and was in compliance with the requirements at a
facility accredited by the American Association for Accreditation of Laboratory Animal
Care. Whole blood samples were collected by jugular venipuncture with a 20-gauge
needle directly into a glass vacutainer tube containing 0.5mL of PECT medium (94nM
prostaglandin E1, 0.63mM Na2CO3, 90mM EDTA, and 10mM theophylline) that had an
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approximate draw of 5mL. Sample preparation was initiated within one hour on the day
of collection and initial blood cell counts were performed by an automated cell counter
(Cell-Dyn 3700, Abbott Laboratories, Abbott Park, IL, USA).
A 1.063 g/mL density barrier was created by combining 5 mL of 1.320 g/mL 60%
iodixanol stock solution (OptiPrep density gradient medium, Sigma-Aldrich, Saint Louis,
MO, USA) with 22mL diluent (0.85% NaCl, 20mM HEPES-NaOH, pH 7.4, 1mM
EDTA). For platelet separation, 3mL of each sample were layered over 5mL of the
1.063g/mL density barrier. Layered samples were then centrifuged at 350xg for 15
minutes at 20°C in a swinging bucket rotor with the brake turned off [11,12]. One
milliliter of the concentrated, opaque platelet fraction was collected as illustrated (Figure
1). Further removal of residual contaminating leukocytes was performed by coupling
magnetic beads (Sheep anti-rat IgG Dynabeads, Invitrogen Dynal, Oslo, Norway) with rat
anti-dog CD45 antibody (AbD Serotec, Raleigh, NC, USA), incubating the beads with
the platelet sample for thirty minutes at room temperature with gentle rotation, and
placing the mixture in a specialized magnet according to the manufacturer’s protocol.
Cells in before and after bead depletion samples (platelets, leukocytes, and erythrocytes)
were counted manually using a hemocytometer (improved Neubauer, Hausser Scientific
Co., Harsham, PA, USA) to assess sample recovery and purity.
Flow cytometry
Flow cytometric analysis was performed with a flow cytometer using Cell Quest
Pro software (FACScalibur, BD Biosciences, San Jose, CA, USA). In order to assess
sample purity, double staining with RPE-anti-CD45 (Rat anti-dog CD45: RPE,
MCA1042PE, AbD Serotec, Raleigh, NC, USA) and FITC-anti-CD61 (Mouse anti99

human CD61: FITC, BD Pharmingen, San Jose, CA, USA) were performed. One
hundred microliters of sample were incubated with 10μL of anti-CD45 and 20μL of antiCD61 for 20 minutes at room temperature. The samples were washed and resuspended in
phosphate buffered saline for analysis. Samples were displayed on log forward-angle
versus log side-angle light scatter plots. Gates were determined to include all blood cells
and results visualized on a dual color quadrant.
We also employed an automated leukocyte count technique, which relies on
propidium iodide DNA staining and on test tubes containing precise numbers of
fluorescent beads to quantify the residual leukocyte, according to manufacturer’s protocol
(LeucoCOUNT Reagent Kit, BD Biosciences). For each sample 30,000 bead events were
counted.
Platelet activation was assessed using fluorescent-labeled Annexin V (FITC
Annexin V, BD Biosciences) and RPE-anti-CD62P (P-selectin) (Mouse anti-human
CD62P: RPE, MCA2419, AbD Serotec) binding and flow cytometric analysis. Annexin
V binds exposed phosphatidylserine on the platelet membrane, a platelet membrane
phospholipid that is trans located from the inner membrane leaflet to the exposed outer
surface during platelet activation [12]. P-selectin is a platelet granule membrane protein
that translocates to the outer membrane surface after activation and granule release [13].
For Annexin V labeling, around 5 million platelets (after OptiPrep and after Dynabeads)
were spun down and resuspended in binding buffer before staining with 1:10 diluted
Annexin V according to the manufacturer’s protocol. For P-selectin labeling, 20uL of
RPE-anti- CD62P antibody were added to platelet samples the same as described above
for CD45 and CD61 labeling. For positive controls, platelets were activated with 1U/ml
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of thrombin and 10ug/mL collagen. Platelet populations were displayed on log forwardangle versus log side-angle light scatter plots. Gates were adjusted to platelet populations,
and 5,000-gated events were recorded for each labeling. Expression was quantified by the
percent of positive events for Annexin V and P-selectin.
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Figure 3.1

Density barrier layering before and after centrifugation with whole blood.
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Figure 3.2

Flow cytometric analyses of optimized platelet samples after density barrier
centrifugation.

(A) Log forward and side scatter chart of platelet population (gated) with minimal
contaminating cells. (B) Fluorescence chart of CD45 (FL2) and CD61 (FL1) antibodylabeled samples. Average CD61+: 99.47 ± 0.21% (n = 3). Average CD45+: 0.19 ±
0.04% (n = 3). (C) LeucoCOUNT chart for sample showing residual leukocytes (left
gate) and LeucoCOUNT beads (right gate).
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Figure 3.3

Flow cytometric analyses of optimized platelet samples after CD45-labeled
Dynabead incubation.

(A) Log forward and side scatter chart of platelet population (gated) of platelet sample
with minimal contaminating cells. (B) Fluorescence chart of CD45 (FL2) and CD61
(FL1) antibody-labeled sample. Average CD61+: 97.99 ± 1.38% (n = 12). Average
CD45+: 0.43 ± 0.33% (n = 12). (C) LeucoCOUNT chart for sample after density barrier
centrifugation showing residual leukocytes (left gate) and LeucoCOUNT beads (right
gate).
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Figure 3.4

Flow cytometric analyses of platelet activation by Annexin V labeling.

(A) Collagen activated platelets. (B) Platelet sample after density barrier centrifugation.
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Figure 3.5

Flow cytometric analyses of platelet activation by P-selecting labelling.

(A) Thrombin activated platelets. (B) Platelet sample after density barrier centrifugation.
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Abstract
During platelet development, proteins necessary for the many functional roles of
the platelet are stored within cytoplasmic granules. Platelets have also been shown to take
up and store many plasma proteins into granules. This makes the platelet a potential
novel source of biomarkers for many disease states. Approaches to sample preparation
for proteomic studies for biomarkers search vary. Compared with traditional twodimensional polyacrylamide gel electrophoresis systems, nonelectrophoretic proteomics
methods that employ offline protein fractionation methods such as the differential
detergent fractionation method have clear advantages. Here we report a proteomic survey
of the canine platelet proteome using differential detergent fractionation coupled with
mass spectrometry and functional modeling of the canine platelet proteins identified. A
total of 5,974 unique proteins were identified from platelets, of which only 298 (5%) had
previous experimental evidence of in vivo expression. The use of offline prefractionation
109

of canine proteins by differential detergent fractionation resulted in greater proteome
coverage as compared with previous reports. This initial study contributes to a broader
understanding of canine platelet biology and aids functional research, identification of
potential treatment targets and biomarkers, and sets a new standard for the resting platelet
proteome.
Introduction
The roles that platelets play in blood hemostasis, wound healing, inflammation,
and thrombus formation are well described, and more recently, platelets have also been
recognized for their interactions with tumor cells [1]. During platelet development,
proteins necessary for the many functional roles of the platelet are stored within
cytoplasmic granules. Platelets have been shown to take up and store many plasma
proteins into granules. This makes the platelet a potential novel source of biomarkers for
many disease states [2]. Naturally occurring disease in the dog, a companion animal of
veterinary importance, is gaining recognition as a valuable model of human disease [3,4].
Translational studies focusing on identification of novel platelet protein markers for
disease using the dog first require a description of the basal canine platelet proteome.
This will allow for the necessary comparison of the canine and human platelet proteome.
Approaches to sample preparation for proteomic studies vary. Compared with
traditional two-dimensional polyacrylamide gel electrophoresis systems,
nonelectrophoretic proteomics methods that employ offline protein fractionation
methods, such as the differential detergent fractionation (DDF) method described by
McCarthy et al [5], have clear advantages. This technique, for instance, increases the
yield of hydrophobic membrane proteins due to protease digestion based on the
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physicochemical properties of peptides. Because the DDF method assigns GO (Gene
Ontology) cellular component terms to proteins based on the detergent fraction they were
extracted in, as well as the number of transmembrane domains the protein contains, it
allows identification of the subcellular localization of proteins expressed within the cell.
Here we report a proteomic survey of the canine platelet proteome using DDF, mass
spectrometry, and subsequent functional modeling. The canine platelet proteome
described here provides evidence for in vivo expression or uptake of these proteins in the
canine platelet. Additionally, since the method used for protein fractionation could
predict subcellular localization of the proteins, we could also add to the “cellular
component” of protein functional annotation based on subcellular localization as
described below.
Materials and methods
Platelet isolation
Normal resting platelets were purified from the blood (collected in
ethylenediaminetetraacetic acid) of three adult healthy female Walker hounds. Whole
blood (3mL) was layered on top of 3mL of a 1.077g/mL density gradient and spun at
400g for 30 minutes at room temperature. The resulting top fraction was washed with
HEPES-NaCl, layered over a combination of diluted 60% iodixanol 1.32g/mL density
barriers (10% and 13% stock solution, from top to bottom), and spun at 300g for 20
minutes. The top fraction was washed, pelleted, and resuspended in HEPES-NaCl. Cell
counts were performed manually with a hemocytometer and samples were found to have
an d The sample was then pelleted again and stored at −80oC. Platelet pellets from a total
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of 20mL of blood from each dog were subjected to protein extraction (average of 4.7 ±
4.1 × 108 total platelets).
Protein extraction and identification
Proteins were isolated as previously described [5]. Briefly, four different
extractions using digitonin, Triton X-100, deoxycholate plus Tween 40, and sodium
dodecyl sulfate were used to sequentially isolate proteins based upon decreasing
solubility. Each of the fractions was precipitated with 25% trichloroacetic acid to remove
salts and detergents, and trypsin digested. Peptides were desalted and then cleaned using
a reverse phase macrotrap and strong cation exchange macrotrap (Michrom Bioresources
Inc., Auburn, CA, USA), respectively, according to the manufacturer’s instructions.
Samples were then dried and resuspended in 2% acetonitrile, 0.1% formic acid.
Peptide mass spectrometry was accomplished using an EASY-nLC (Thermo
Scientific, Rockford, IL, USA) high performance liquid chromatography machine
coupled with an LTQ Velos linear ion trap mass spectrometer (Thermo Scientific). The
Easy-nLC was configured for reverse phase chromatography using a Hypersil Gold
KAPPA C18 column (Thermo Scientific) with a flow rate of 333 nanoliters per minute.
Peptides were separated for mass spectrometry analysis using an acetonitrile gradient
starting at 2% acetonitrile, 0.1% formic acid and reaching 50% acetonitrile, 0.1% formic
acid in 120 minutes, followed by a 15-minute wash of 95% acetonitrile, 0.1% formic
acid. Column equilibration was handled automatically using the EASY-nLC. The eluate
from the high performance liquid chromatography was fed directly to the LTQ Velos for
nanospray ionization followed by tandem mass spectrometry analysis of detected
peptides. The LTQ Velos was configured to perform one mass spectrometry scan
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followed by 20 tandem mass spectrometry scans of the 20 most intense peaks repeatedly
over the 172-minute duration of each high performance liquid chromatography run.
Dynamic exclusion was enabled with a duration of 5 minutes, repeat count of one, and a
list length of 500. The collected spectra were subsequently analyzed using the X!Tandem
(Open-source software, The Global Proteome Machine Organization) search algorithm
[6].
Raw spectral data from the LTQ Velos were converted to mzML format using the
msConvert tool from the ProteoWizard (Open-source software) software project [7]
because X!Tandem cannot read the Thermo raw format directly. The FASTA database
used for peptide spectrum matching (target database) was the Canis familiaris RefSeq
protein database from the National Center for Biotechnology Information. X!Tandem
was configured to use tryptic cleavage sites with up to two missed cleavages. Precursor
and fragment mass tolerance were set to 1000 ppm and 500 ppm, respectively. Four
amino acid modifications were included in the database search, ie, single and double
oxidation of methionine and both carboxymethylation and carboxamidomethylation of
cysteine. A decoy search was also performed using a randomized version of the target
database with the same search parameters as before. The search results were filtered
using the methods described previously [8,9]. A decoy score distribution of X!Tandem
hyperscores and e-values was created and each match from the target database was
evaluated as a possible outlier and assigned a probability of being such. Peptides from the
target database were accepted if the probability of being an outlier was 95% or higher. A
list of proteins and identified peptides was generated for each experimental sample.
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Functional analysis of platelet proteome
Platelet proteins identified using mass spectrometry were analyzed using AgBase
tools (Open-source software, Agbase, Mississippi State University) [10]. GORetriever
(Open-source software, Agbase, Mississippi State University) was used to obtain GO
annotation and these results summarized using GOSlimViewer with the Generic Slim set
[11]. We compared the function of the platelet proteome against the GO for the entire GO
proteome by downloading the dog gene association file from AgBase (December 14,
2012) and comparing the relative proportions for each slimmed GO term.
Platelet proteins identified by mass spectrometry were also analyzed using
DDF2GO [12], a tool that groups proteins into GO cellular component categories based
on the fraction they were extracted in as well as their number of transmembrane domains,
predicted using PSORTII [13] (Open-source software, Human Genome Center, Tokyo,
Japan) and TMpred [14] (Open-source software, TMbase) online prediction softwares.
DDF2GO uses a GO CC mapping table, previously established by studies from
McCarthy et al using proteins’ DDF fractions and transmembrane domains, which
dictates GO CC assignment conditions based on DDF fraction percentages and average
transmembrane domains [5]. Since platelets are anucleate, the annotations to the GO term
“nucleus” were not included in the results.
Pathways analysis
We used Ingenuity Pathways Analysis (Ingenuity Systems Inc., Redwood City,
CA, USA) to identify significant molecular functions and canonical pathways represented
by platelet proteins as described earlier [15]. A right-tailed Fisher’s Exact test was used
to calculate a P-value determining the probability that each biological function assigned
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to that data set is due to chance alone. All molecular functions and metabolic and
signaling pathways identified at a P-value of <0.05 were considered to be statistically
significant.
Results
Protein identification
We identified 5,974 unique proteins from platelets collected from three healthy
dogs (http://www.dovepress.com/cr_data/ supplementary_file_47127.pdf). Only 298
(5%) of these identified proteins had previous experimental evidence of in vivo
expression. The remaining 5,676 (95%) of the identified proteins are computationally
predicted based on homology to known proteins in related species.
Functional analysis
Our GO analysis of the proteins identified by mass spectrometry indicated that
86% of the 5,974 proteins we identified had GO annotation. Using the generic GO Slim
to summarize the GO function for our proteins, we identified the general functions
represented in our data set. The most under-represented and over-represented GO
functions in the canine platelet proteome dataset compared with the canine genome are
shown in Figure 1, and the top ten GO terms for each ontology are shown in Figure 2.
Compared with the canine genome, our canine platelet proteome was highly
enriched in the GO biological process terms “cytoskeleton organization”, “cell
recognition”, “cellular component organization”, “cell communication”, “cell-to-cell
signaling”, and “response to endogenous/ exogenous stimulus”, which can be related to
important functions in platelets. The GO terms “translation” and “secondary metabolic
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process” were found to be under-represented in the canine platelet compared with the
genome as would be expected considering the platelets’ lack of nuclei. The most
represented GO biological process terms were “unknown” (36.20%), “anatomical
structure development” (7.33%), and “signal transduction” (5.15%). The last two terms
reflect the importance of intracellular signaling and structural changes in platelet
function. In hemostasis, platelet surface receptors will bind to exposed subendothelial
proteins upon vascular injury, which leads to platelet activation and morphologic change
from a discoid to a spherical shape.
In comparison with the dog genome, our platelet proteome was highly enriched in
the GO cellular component terms “cytoplasmic membrane-bound vesicle”, “endosome”,
“proteinaceous extracellular matrix”, “organelle”, “plasma membrane”, and
“cytoskeleton”. All of these GO terms highly enriched in the platelet are important to
platelet function and morphology in normal hemostasis. Some under-represented GO
terms in the platelet versus the genome included “nuclear”, “ribosome”, and “lipid
particle”, which is not surprising considering platelets are anucleate and lack normal
nucleated cell translational levels and membrane assembly. The most represented GO
terms were “unknown” (22.03%), “cell” (14.49%), “intracellular” (13.46%), “cytoplasm”
(8.73%), and “organelle” (8.28%). These localization categories are rather general and
only indicate that within the proteins with known localization, the majority are annotated
as being anywhere in the cell, including the membrane (cell) or not (intracellular).
Highly enriched protein GO molecular function terms present in the platelet
compared with the dog genome included “protein binding”, “carbohydrate binding”,
“enzyme regulator activity”, “cytoskeletal protein binding”, “actin binding”, and
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“receptor binding”, all of which are related to important platelet functions. Some of the
most under-represented GO terms in this category are “structural constituent of
ribosome” and “mRNA binding” which, again, make sense considering the anucleate
nature of platelets and their limited protein translation functions. The most represented
GO molecular function terms were “unknown” (49.16%), “ion binding” (12.63%),
“kinase activity” (4.59%), “DNA binding” (3.92%), and “transmembrane transporter
activity” (3.13%), which emphasize the importance of signaling in platelets.
In order to evaluate pathways and processes further, we used Ingenuity Pathway
Analysis (Ingenuity Systems Inc.) software to obtain the significantly represented
functions and pathways in the canine platelet proteome, as shown in Figures 3 and 4. In
the analysis of the canine platelet proteome, “hematological system development and
function”, “inflammatory response”, “cancer”, and “cellular movement” were among the
top represented functional categories found in the canine platelet. These categories
indicate the multifunctionality of platelets, which play important roles in inflammation
and cancer development in addition to their hemostasis function [1]. The three most
represented functions include “cellular assembly and organization”, “cellular function
and maintenance”, and “cell morphology”, which illustrates functions that are important
during platelet activation and hemostatic function.
The most significant canonical pathways are shown in Figure 4. “Thrombin
signaling”, “HGF signaling”, “EGE signaling”, “PDGF signaling”, “integrin signaling”,
and “thrombopoietin signaling” were among the top represented canonical pathways
listed for the canine platelet. The proteins in these canonical pathways have significant
roles in hemostasis, clot formation, wound healing, and angiogenesis. The presence of the
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“actin cytoskeleton” pathway as being the fifth most significant corroborates with the
over-representation of cytoskeleton proteins indicated by the GO analysis results.
Subcellular localization of proteins
Platelet proteins were extracted using DDF, a multistep protein extraction method
that uses four detergents (digitonin, Triton X-100, deoxycholate plus Tween 40, and
sodium dodecyl sulfate) to separate proteins into four protein fractions based on
decreasing solubility. Subsequent analysis of proteins extracted using DDF was
performed using DDF2GO [12] software which assigns cellular component-specific GO
terms to each protein based on the detergent fraction the protein was extracted in and the
number of transmembrane domains in the protein, if any.
Three healthy dog platelet samples were used for this proteomic study with an
average of 2,668 proteins identified from each dog. We identified 1,803 proteins common
to more than one dog which we then further analyzed to identify where these proteins
were located in the platelet based on GO terms from DDF2GO.
The DDF method we used isolates proteins from throughout the entire platelet, as
graphically illustrated in Figure 5 using cellular component terms from GOSlimViewer
(Open- source software, Agbase, Mississippi State University) for proteins found in more
than one of the three dogs. About 42% of the protein annotations were related to
membranes, approximately 17% of which were to the plasma membrane in particular.
Nearly 36% were related to organelles, with 10%, 3%, and 2% belonging to the
mitochondrion, vesicle, and endoplasmic reticulum categories, respectively. About 22%
of annotations related to the cytoplasm. These annotations indicate that the proteins found
in more than one dog are located in the same subcellular regions.
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In our platelet protein analysis we observed up to a 4.9- fold increase in
information about subcellular localization using DDF2GO for protein functional analysis
compared with AgBase’s GORetriever. DDF2GO provides protein annotation outputs
that are different from traditionally used software like GORetriever. Tools such as
GORetriever assign protein annotations in light of what is already known about the
proteins. In addition to what is already known about the proteins, DDF2GO allows us to
look at proteins based on the detergent fraction(s) that the protein was extracted in as well
as the number of transmembrane domains the protein has. Proportionally, we observed a
4.0-fold increase in protein annotations related to “plasma membrane” and a 2.3-fold
increase related to “cytoplasm”. The “mitochondrion” and “endoplasmic reticulum” GO
cellular component categories had 4.9-fold and 1.6-fold increases in annotations for
proteins in their categories, respectively. Use of DDF2GO software for protein annotation
adds experimentally derived functional information, improving our functional analysis of
the canine platelet proteome.
Discussion
In this report, we describe the canine platelet proteome and provide the first in
vivo expression evidence of these proteins in the dog. We identified 2.4-fold more
proteins than the most comprehensive platelet proteome previously reported [16].M The
number of proteins we found is also higher than previous human platelet predictions of
2,000–3,000 proteins [17] and the most recent estimate of 5,000 proteins [18]. This is
likely due to the fact that previous studies used two-dimensional electrophoresis for
protein separation. This technique is commonly used for proteomics but has the
disadvantage of low yields of membrane, basic, high molecular weight and some
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signaling proteins [19,20]. Our non-gel-based mass spectrometry coupled with DDF
ensured a comprehensive proteome.
The fact that the majority of the proteins are categorized as “unknown” in all three
ontologies reflects that there are still a significant number of proteins for which we have
little or no functional information. This is a recognized problem across a large range of
species [21]; however, tissue expression data frequently provides the first clues to protein
function and we report that these proteins are expressed in platelets.
The DDF technique offers unique advantages to protein extraction in that it does
not disrupt cellular architecture. The first detergent used in DDF, ie, digitonin, efficiently
isolates soluble cytosolic proteins due to how it interacts with cholesterol to form pores in
the cell membrane. Triton X-100, the second sequential detergent used, solubilizes
membrane and organelle proteins, while the third detergent used, ie, a combination of
deoxycholate and Tween 40, extracts the soluble nuclear fraction. Sodium dodecyl sulfate
is the final detergent used in DDF which primarily isolates the more insoluble proteins as
well as nuclear matrix proteins [5]. Because of this, proteins isolated in different
detergent fractions prior to mass spectrometry analysis can allow identification of protein
subcellular localization.
In our platelet protein analysis, we observed up to a 4.9-fold increase in
information about subcellular localization using DDF2GO for protein functional analysis
compared with AgBase’s GORetriever. Traditional protein functional analyses employ
software such as GORetriever, which annotates proteins based on existing annotations for
a given list of proteins. Not only does DDF2GO software factor in a protein’s existing
annotation, but also considers the detergent fraction(s) that the protein was extracted in as
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well as the number of transmembrane domains if the given protein is a membrane
protein. These additional considerations involved in annotation assignment by DDF2GO
allow addition of knowledge as to where the protein came from and the proportion found
in that subcellular location. This addition of experimentally derived functional
information not only improves our functional analysis of the canine platelet proteome,
but also confirms the suspicion that the knowledge of protein function and subcellular
localization is incomplete. Use of DDF2GO allowed us to have improved coverage of
subcellular localization data throughout the platelet.
Interestingly, there was a relatively high amount (7.15%) of proteins categorized
as “nuclear”, which at first seems counterintuitive, since platelets are anucleate, although
this finding is in accordance with reports from other studies [22-24]. The presence of
nuclear protein in platelets is not well understood and their possible role in platelet
function is yet to be determined [22,25]. One of the explanations for this finding takes
into account the nature of the GO terms and how functional modeling relies on biological
knowledge; while proteins are annotated to the nucleus, they also have other subcellular
localizations and the GO annotation is not context-dependent. In our data, 71% of the
proteins annotated as “nuclear” were also found to have other annotations in the GO
cellular component category. Moreover, nuclear proteins may represent, in part,
contamination by residual leukocytes. However, we believe that was not an issue in our
analysis, since our samples were of high purity (99.98% by manual count), in accordance
with some of the few studies that actually address sample contamination [16, 23, 24].
Lastly, it has been stated that dog platelets can sometimes present fragments of nuclear
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material [26]. Thus, considering this affirmation, the presence of nuclear components in
platelet proteome analysis would be normal and expected.
Using DDF2GO software for platelet protein annotation analysis, the annotations
we add are specific for proteins expressed in platelets. The nuclear category of GO terms
and annotations are excluded from the output production. For the currently described rat
and human platelet proteomes [16-18, 24], the technique for platelet protein analysis
described here has not been used.
Conclusion
This initial study contributes to a broader understanding of canine platelet biology
and aids functional research, identification of potential treatment targets and biomarkers,
and sets a new standard for the resting platelet proteome.
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Canine platelet proteome GO categories compared with the canine genome.

The graphs show important under-represented and over-represented GO functions in canine platelets. The y-axis shows the categories within functional
groups and the x-axis displays the relative difference between the percentages of the categories in the platelet proteome and the percentages in all canine GO
annotations.

Figure 4.1

Figure 4.2

Top ten GO categories in resting canine platelets compared with all canine
annotations.

Top ten GO categories in resting canine platelets (dark gray bars) compared with all canine
annotations (light gray bars) for the three gene ontologies: biological process, cellular component,
and molecular function. Categories are represented as percentages of the total.
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Figure 4.3

Ten most significant biological functions represented in resting canine
platelets proteome.

The chart displays biological functions along the x-axis and significance in y-axis. The
threshold line demonstrates the limit for significance (P = 0.05).

125

Figure 4.4

Ten most significant canonical pathways represented in resting canine
platelet proteome.

Pathways are shown along the x-axis and the significance in the left y-axis. The threshold
indicates the limit for significance (P = 0.05). The ratio is the number of proteins that
meet the cutoff criteria divided by the total number of proteins in the pathway.
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Figure 4.5

Subcellular localization of the platelet proteins found in more than one dog
by DDF2GO.

The complete list of 1,803 platelet proteins from this study was used in determining the
subcellular localization of the identified proteins using DDF2GO software. This figure
shows the results for each of the identified categories as a pie chart. Each category and
the relative percentage of total proteins present in that category are shown in the graph.
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EFFECTS OF PLATELET LYSATE ON THE PROTEOME OF CANINE
OSTEOSARCOMA AND MAMMARY TUMOR CELLS IN VITRO
Abstract
Background
Osteosarcoma and mammary tumors affect both humans and canines with high
metastatic rates and poor prognosis in many cases. Most canine patients (and many
human patients) have pulmonary metastases already in place at the time of diagnosis,
which illustrates the importance of early detection of these neoplasms for earlier
treatment initiation to improve outcome and prognosis overall. Platelets have been shown
to have an active and important role in tumor cell growth and metastasis, long since
expanding their function beyond just hemostasis. Limited evidence is present, though,
concerning the specific roles and effects of canine platelets in cancer growth and
progression. In this study, platelet lysate was incubated with three tumor cell lines
(OSA8, OSA40, and CMT28) in vitro. Proteomic analysis was performed on the samples
after protein isolation and mass spectrometry was performed.
Results
Multiple proteins were found to be differentially expressed for each of the cell
lines including proteins that have been proven to have roles in tumor cell survival,
growth, migration, and metastasis, as well as proteins involved in tumor cell apoptosis
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and suppression. Some proteins were found identified to be up or down regulated for
more than one tumor cell line.
Conclusions
Overall, the many of the proteins found to be differentially expressed after
incubation of platelet lysate with canine osteosarcoma and mammary carcinoma cell lines
suggest that platelets promote tumor cell growth and migration when compared to
controls. In contrast, some proteins identified as having differential expression following
platelet lysate incubation have anti-tumor and anti-metastatic functions. These contrasting
findings further represent the dynamic nature of cancer itself in the battle between tumor
survival and progression and the host response to combat the invading erroneous cells.
Introduction
Cancer is a disease that research has been devoted to tirelessly over the past
century in an attempt to understand and counteract its wide range of effects that
ultimately lead to high morbidity and mortality worldwide in both humans and animals.
A novel theory has recently been accepted that cancer is not merely normal cells of the
body that have gone rogue, but rather a disease caused by the body’s inability to manage
these erroneous cells – a disease of imbalance [1]. Regardless of species, the majority of
deaths caused by cancer are due to metastasis (more than 90%). In the body, some tumor
cells undergo a cascade of events starting with epithelial to mesenchymal transition
(EMT) [2]. From this transition, these cells detach from the primary tumor site, enter into
the vasculature, survive circulation despite shearing forces and immune system
surveillance, and ultimately start a new tumor at a distant site within the body [3, 4].
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Tumor cell invasion and metastasis are the main foundation of tumor biology that
ultimately lead to death.
Osteosarcoma (OSA) is the most common bone tumor of both humans and
canines with a notorious reputation for being highly aggressive in both species [5, 6]. In
humans, with children and adolescents primarily being affected, distant metastasis occurs
in 45% of cases regardless of treatment protocols utilized [7]. In canines, although the
standard treatments including limb amputation/sparing, chemotherapy and radiotherapy
have significantly increased survival rates, almost 90% of dogs will eventually develop
predominantly pulmonary metastases [6]. The majority of these tumors occur in the
appendicular skeleton of middle-aged large and giant breeds. Roughly 10,000 new cases
of OSA are identified in dogs annually [6]. Prognosis remains poor, with average disease
free intervals of 10 months and median survival times ranging from 3 months to 1 year.
Less than 20% of dogs survive for more than 2 years following diagnosis [8, 9]. Since
most cases already have pulmonary metastasis by the time of diagnosis (which may or
not be visual on imaging), early detection is key in being able to treat and improve
prognosis in these patients.
Some of the most common gynecological neoplasias in both humans and canines
are mammary tumors [10, 11]. Malignant canine mammary tumors have been reported to
have an incidence of up to 50% [12, 13]. Distant and local metastasis may occur in both
human and canine malignant mammary tumors, and relapse often occurs following
surgical excision [14]. Canine mammary tumor cells have successfully been used for
years as in vitro models for human breast cancer research based on clinical similarities,

133

spontaneous occurrence, intraepithelial lesions, hormonal influences, and age of onset
[15, 16, 17, 18].
Platelets have many well-known roles involving blood hemostasis, wound
healing, inflammation, thrombus formation, and more recently recognized interactions
with tumor cells and metastasis [19]. Thrombocytosis has long been associated and
documented with neoplasias, particularly metastatic malignant neoplasms [20, 21]. These
anucleate, disc-shaped cells contain three different types of granules, alpha granules,
dense granules, and lysosomes [22], which have more recently been believed to have
large roles in contributing to metastatic disease, beyond their more well-known roles in
coagulation and hemostasis. Platelets have the ability to take up and store angiogenesisrelated proteins into specific granules, making them potential sources of biomarkers for
tumor dormancy and growth [23]. Alpha granules contain many proteins primarily
associated with platelet adhesion and aggregation. Dense granules contain very small
substances that aid in platelet recruitment when secreted. Lysosomes mainly have the
task of releasing hydrolase enzymes that are utilized in the breakdown of platelet
aggregates [21]. In addition to angiogenesis-modulating molecules, activated platelets
have been shown to release factors that can modulate hemostasis, inflammation, and cell
proliferation - all of which are necessary for tumors to make a transition from tumor
dormancy to progression. In one study, the injection of tumor cells previously incubated
for 48 hours with washed platelets resulted in increased pulmonary metastasis in mice,
indicating that platelets seem to prime the tumor cells for metastasis [23]. Similarly,
exposure of tumor cells to platelet-derived microparticles (vesicles that are shed from
platelets after activation that contain several adhesive proteins expressed in activation)
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also increased the metastatic potential of the tumor cells [24]. Many studies have shown
that platelets promote metastasis of cancer by providing protection to tumor cells within
the vasculature and cloak the tumor cells from immune surveillance through still
undetermined mechanisms [26, 27, 28].
Limited proteomic information exists regarding canine platelet-tumor interactions
and their effects. Our previous study mapped and described the normal canine platelet
proteome [29]. Here we describe our proteomic findings on the effects of in vitro
incubation of platelet lysate with three different tumor cell lines (OSA8, OSA40,
CMT28).
Methods
Cell Lines and Culture
This experiment utilized two canine osteosarcoma cell lines (OSA8 and OSA40)
established from dogs with spontaneously occurring osteosarcoma [30]. A canine
mammary carcinoma cell line (CMT28) was established from dogs with spontaneously
occurring mammary carcinoma [31]. Cell lines were maintained in culture medium
consisting of Dulbecco’s modified Eagle’s medium (DMEM) (Gibco, Grand Island, New
York, USA) containing 10% FBS (Gibco, ThermoFisher Scientific, USA), 0.2%
Primocin (InvivoGen, San Diego, California, USA), and 1% HEPES buffer solution
(Sigma-Aldrich) at 37oF and maintained at 5% CO2.
Platelet Purification
Whole blood was collected from three healthy female Walker hounds via jugular
venipuncture with a 20-gauge needle using 3.2% sodium citrate anticoagulant. Special
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care was taken on blood draw technique to prevent platelet activation. Animal use was
approved by the Mississippi State University Institutional Animal Care and Use
Committee and was in compliance with the requirements at a facility accredited by the
American Association for Accreditation of Laboratory Animal Care. To maintain a ratio
of 100 platelets per tumor cell, 20mL of blood was collected from each dog. Sample
preparation was initiated within one hour of collection. Platelet-rich plasma (PRP) was
obtained by spinning the blood at 1200g for 2 min with the brake setting at level 2 in
5mL Eppendorf tubes in a spinning bucket rotor. The top ¾ of PRP was collected and the
protocol for PRP repeated. PRP was then layered over an Optiprep density barrier using
the technique reported in Trichler et al 2013 [29]. Briefly, 3mL of PRP was placed over
5mL of a 1.063g/dL Optiprep density barrier in a 15mL Falcon tube. The tubes were then
centrifuged at 350g for 15min in a spinning bucket rotor with the brake turned off and the
temperature set to 20oC. After spinning, 1mL of the ‘platelet rich layer’ was collected for
further processing and lysis. The ‘platelet rich layer’ sits below the plasma layer and has
a very opaque to white appearance around the 4-5mL mark on the 15mL conical
centrifuge tube.
All samples were analyzed for platelet, leukocyte, and erythrocyte numbers using
a hemocytometer (improved Neubauer, Hausser Scientific Co., Harsham, PA, USA).
Platelets and erythrocytes were counted by diluting the final sample obtained after the
Optiprep step 1:20 with phosphate buffered saline (PBS). To monitor for any residual
leukocytes in the samples, a 1:2 dilution with Turk’s solution was used to stain any
leukocytes present. For all samples collected and purified, no leukocytes or erythrocytes
were observed after staining. Cell counts were used to calculate the volume of each
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sample needed to produce an overall ratio of 100 platelets per cancer cell for each
experimental sample.
Platelet Lysate preparation
Platelet lysate was prepared using a sonicator (Q Sonica LLC, Newtown, CT,
model Q125, probe model CL-18) on each Optiprep sample for 10 bursts of 5 seconds
with 1 minute intervals between each burst. After lysis, samples were checked for
residual intact platelets using a hemocytometer (improved Neubauer, Hausser Scientific
Co., Harsham, PA, USA). Once residual platelets were no longer observed, samples were
centrifuged at 10,000g for 10 minutes at 4oC. Supernatants were pooled for all of the
samples from the three different dogs. The pooled samples were used with the
experimental samples in vitro.
Cell culture with platelet lysate
Cancer cells from each cell line (OSA8, OSA40, and CMT28) were harvested
from T75 flasks (Thermo Scientific, Waltham, Massachusetts, USA) that were at 90100% confluency and counted using Trypan Blue staining. One million cells were seeded
into nine T25 flasks (Thermo Scientific, Waltham, Massachusetts, USA) and allowed to
attach overnight in 10% FBS containing DMEM medium at 37oC with 5% CO2. The
following day, existing medium was removed while leaving cells attached to the flask.
Platelet lysate was combined with cell culture medium using the previously established
volume to represent a ratio of 100 platelets per cancer cell (100,000,000 platelets). To
prevent clot formation in the flasks due to lysate addition, 4U/mL Heparin (SigmaAldrich) was prepared with 10% FBS containing DMEM medium. For control samples,
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Optiprep density barrier was added in place of platelet lysate at the same volume.
Experimental samples for each cell line included 8 hour incubations of lysate and control
samples as well as a zero hour control. All samples were run in triplicate.
After incubation, samples were trypsinized using 0.25% Trypsin-EDTA (Gibco,
ThermoFisher Scientific, USA) and centrifuged at 450g for 5 minutes at room
temperature. All samples were stained with Trypan Blue and cell recovery was estimated
by determining cell counts with a Neubauer hemocytometer to evaluate cell recovery.
Cell pellets were then washed three times using 10mL sterile PBS (Sigma-Aldrich) and
centrifuged at 450g for 10 minutes at room temperature. The final pellet was
resususpended in 1mL sterile PBS, pelleted at 450g for 10 minutes, and immediately
frozen in liquid nitrogen after removal of the supernatant.
Sample Digestion
Protein pellets were solubilized in 100µL of 6M urea in 50mM ammonium
bicarbonate (AMBIC). 200mM of dithiothreitol (DTT) was added to a final concentration
of 5mM and samples were incubated for 30min at 37°C. Next, 20mM iodoacetamide
(IAA) was added to a final concentration of 15mM and incubated for 30min at room
temperature, followed by the addition of 20 µL DTT to quench the IAA reaction. LysC/trypsin (Promega) was next added in a 1:25 ratio (enzyme:protein) and incubated at
37°C for four hours. Samples were then diluted to <1M urea by the addition of 50mM
AMBIC and digested overnight at 37°C. The following day, samples were desalted using
C18 Macro Spin columns (Nest Group) and dried down by vacuum centrifugation.
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LC-MS/MS Analysis
LC separation was done on a Waters Nano Acquity UHPLC (Waters Corporation)
with a Proxeon nanospray source. The digested peptides were reconstituted in 2%
acetonitrile /0.1% trifluoroacetic acid and roughly 3µg of each sample was loaded onto a
100 micron x 25 mm Magic C18 100Å 5U reverse phase trap where they were desalted
online before being separated on a 75 micron x 150 mm Magic C18 200Å 3U reverse
phase column. Peptides were eluted using a gradient of 0.1% formic acid (A) and 100%
acetonitrile (B) with a flow rate of 300nL/min. A 120-minute gradient was run with 5%
to 35% B over 100 minutes, 35% to 80% B over 8 minutes, 80% B for 1 minute, 80% to
5% B over 1 minute, and finally held at 5% B for 10 minutes. Each of the gradients was
followed by a 1h column wash.
Mass spectra was collected on an Orbitrap Q Exactive Plus mass spectrometer
(Thermo Fisher Scientific) in a data-dependent mode with one MS precursor scan
followed by 15 MS/MS scans. A dynamic exclusion of 15 seconds was used. MS spectra
were acquired with a resolution of 70,000 and a target of 1 × 106 ions or a maximum
injection time of 30ms. MS/MS spectra were acquired with a resolution of 17,500 and a
target of 5 × 104 ions or a maximum injection time of 50ms. Peptide fragmentation was
performed using higher-energy collision dissociation (HCD) with a normalized collision
energy (NCE) value of 27. Unassigned charge states as well as +1 and ions >+5 were
excluded from MS/MS fragmentation.
Data Analysis
Scaffold (version Scaffold_4.5.1, Proteome Software Inc., Portland, OR) was
used to validate MS/MS based peptide and protein identifications. Peptide identifications
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were accepted if they could be established at greater than 95.0% probability by the
Scaffold Local FDR algorithm. Scaffold then probabilistically validates these peptide
identifications using the Peptide Prophet algorithm [31] and subsequently verifies peptide
identifications assigned by SEQUEST, Mascot, and other search engines using the
X!Tandem database searching program [32, 33]. Protein identifications were accepted if
they could be established at greater than 99.0% probability and contained at least 2
identified peptides. Protein probabilities were assigned by the Protein Prophet algorithm
[34]. Proteins that contained similar peptides and could not be differentiated based on
MS/MS analysis alone were grouped to satisfy the principles of parsimony. Proteins
sharing significant peptide evidence were grouped into clusters. The FASTA database
used for peptide spectrum matching (target database) was the Canis familiaris RefSeq
protein database from National Center for Biotechnology Information (NCBI). Proteins
were also annotated with GO terms from NCBI (downloaded Feb 29, 2016) [35]. Cell
proteins identified using mass spectrometry were analyzed using Scaffold 4.0 (Proteome
Software, Portland, OR, USA) to generate peptide and protein lists using different
filtering methods and statistical tests.
Conservative filter parameters were set for quantitative protein analysis – 99%
protein threshold, minimum number of peptides at 2, and 95% peptide threshold.
Statistical tests including ANOVA and Fishers Exact Tests run on each sample set to
determine proteins/spectra of statistical significance. A Fisher’s Exact test was used to
calculate a P-value determining the probability that each biological function assigned to
that data set is due to chance alone. All molecular functions and metabolic and signaling
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pathways identified at a P-value of <0.05 were considered to be statistically significant
via Scaffold Viewer version 4 software statistical analyses.
Results
Protein Identification
A total of 1632 proteins (376956 spectra) were identified from the OSA8 cell line
samples, 1718 proteins (373864 spectra) for the OSA40 cell line, and 1856 proteins
(372908 spectra) for the CMT28 cell line using conservative filtering parameters in
Scaffold software for quantitative protein analysis as detailed in the Materials and
Methods section.
Identification of differentially expressed proteins
Triplicate samples for each of the three tumor cell lines were analyzed for
samples containing tumor cell lines only, tumor cells briefly exposed to platelet lysate
before being washed, and tumor cells incubated with platelet lysate for eight hours, for a
total of twenty-eight samples to be analyzed by mass spectrometry. The tumor cells were
harvested and subjected to detergent fractionation and digestion before being run through
LC-MS/MS. Entire protein lists are available in supplemental file 2. Using Scaffold
software, protein spectra identified as having a significant difference (P < 0.05) between
samples incubated with platelet lysate for 8 hours and those tumor cells incubated for 8
hours without any exposure to platelet lysate were identified for all three cell lines.
Proteins that also were identified to be significantly different when comparing the platelet
lysate exposed (but not incubated, 0h group) to the tumor cell control samples (no platelet
lysate exposure) were separated out and are explained elsewhere in this manuscript.
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Proteins identified as either significantly increased or decreased after incubation with
platelet lysate are shown in Table 5.1 and illustrated in Figure 5.1 for each cell line
studied.
For all cell lines studied (OSA 8, OSA 40, CMT 28), collagen alpha-1 (Accession
number F1Q3I5_CANLF) was found to be present at significantly lower amounts in the
samples incubated with platelet lysate for 8 hours. No other significant protein changes
were found to be shared between the two OSA cell lines studied. Two proteins were
found to have statistically significant differences in expression between the OSA8 and
CMT28 cell lines, though. Collagen alpha-2 had decreased expression after incubation
with platelet lysate and an ‘uncharacterized protein’ (Accession number
F1PBI6_CANLF) was overexpressed in the platelet lysate incubated samples. This
protein was later identified as being thrombospondin 1 via a Uniprot database search.
OSA8 cell line
After 8 hours of incubation with platelet lysate, seven proteins were identified as
having a significant difference in total spectral count (discounting those that also had a
significant difference at 0h exposure). Increases in protein expression of DNA
topoisomerase 2 (2.9-fold increase), polypeptide N-acetylgalactosaminyltransferase (3.2fold), thrombospondin 1 (8.2-fold), and small nuclear ribonucleoprotein polypeptide A
(14-fold) were identified. Alternatively, decreases in collagen alpha-1 (12-fold decrease),
‘uncategorized protein’ (accession # E2RLJ3_CANLF; 5.3-fold), and collagen alpha-2
(62-fold) were identified.
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OSA40 cell line
Ten proteins were found to be statistically significant in over or under expression
for the OSA40 cell line samples incubated with platelet lysate for 8 hours. Expression of
collagen alpha-1 (4-fold decrease), Nuclear Transport Factor 2 (1.3-fold), and NADH
Dehydrogenase 1 subunit C2 (3-fold) were lower after 8 hours of OSA40 cell incubation
with platelet lysate for 8 hours. In addition, levels of Plasminogen Activator Inhibitor 1
Precursor (16-fold increase), Fibronectin (12.7-fold), Proteasome subunit beta type (4.3fold), Protein phosphatase (14-fold), Zinc finger CCCH-type (6.3-fold), Solute carrier
family 3 (7-fold), and replication protein A2 (5.3-fold) were found to be significantly
increased in samples after 8 hours of incubation with platelet lysate.
CMT28 cell line
Proteins that were increased in total spectra counted for the platelet lysate
incubated samples included Thrombosponsin 1 (4.7-fold increase), Ubiquitin-conjugating
Enzyme E2C (3.2-fold), Small Ubiquitin-related Modifier 2 (3.4-fold), and Nuclear
Casein Kinase and Cyclin-dependent Kinase Substrate 1 (4.8-fold). Collagen alpha-1
(7.6-fold decrease), Collagen alpha-1 Type III (27-fold), Collagen alpha-1 Type V (3.9fold), Collagen alpha-2 (15-fold), NIN1/RPN12 Binding Protein 1 homolog (6.5-fold),
DEAH box polypeptide 15 (3.3-fold), and ‘uncategorized protein’ (access ion number
F1PKU9_CANLF; 11-fold) all had decreased expression after incubation with platelet
lysate. The identification for ‘uncategorized protein’ (F1PKU9_CANLF) in this sample
was not present in different database searches, but GO analysis revealed GO terms
associated including cytochrome-c oxidase activity, being an integral part to the cell
membrane, and also involvement in hydrogen ion transmembrane transport.
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Discussion
Collagen alpha-1 Type I was found to have significantly decreased expression in
all three tumor cell lines studied after incubation with platelet lysate. Collagen alpha-1 is
a fibrillar forming collagen classified as type 1 collagen important in development and
differentiation of different aspects of the skeletal system including endochondral
ossification, osteoblast differentiation, and intramembranous ossification as identified by
GO analysis. Significant decreases in collagen alpha-2 Type I were found for the OSA8
and CMT28 cell line samples in platelet lysate incubated samples. Type 1 collagen is the
archetypal collagen with its primary role being in tissue [36]. The extracellular matrix
(ECM) is an important component of the tumor microenvironment, with collagen being
the most abundant constituent. Traditionally the ECM and its components were thought
of as a scaffold system that formed a generalized barrier against tumor spread. More
recently, though, studies have shown that ECM is able to elicit signaling with effects on
cell migration, cell adhesion, tissue repair and morphogenesis, and angiogenesis [37].
Studies have also shown changes in the ECM in response to cancer – notably a down
regulation in ECM proteolysis compared to the tight regulation seen under normal
circumstances [38, 39]. Interestingly, studies have shown that either an increased or
decreased deposition of collagen can have an association with increased malignancy [40,
41]. During cancer invasion, changes are made within the tumor stroma including
collagen degradation, re-deposition, cross-linking, and stiffening, which ultimately
encourages tumor progression by destabilizing cell polarity and cell-to-cell adhesions [1].
In our samples, the decrease seen across all three cell lines after platelet incubation could
suggest decreased collagen production or increased degradation taking place in response
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to tumor cell exposure. The exposure of platelet proteins and components present in the
lysate over an extended period of time (8 hours) provided the tumor cells with the ability
to overall lead to a decrease in the amount of collagen alpha-1 fragments detectable – the
mechanisms include an increase in degradation or a decreased production of collagen.
Lysyl oxidase (LOX) is a critical enzyme involved in remodeling of the ECM,
and is synthesized either by stromal cells in early carcinogenesis or hypoxic tumor cells
during late stage progression [42, 43]. LOX contributes to collagen cross-linking,
increasing matrix deposition, and increasing tissue stiffness, which in turn enhances
tumor cell adhesion and migration via activated integrins. LOX has been identified as
essential for driving tumor cells to escape from primary tissue sites extravasate, and grow
at secondary sites [44, 45, 46]. Other studies have shown that LOX introduces EMT
(endothelial to mesenchymal transition) and promotes metastatic dissemination in
aggressive and poorly differentiated tumors [47]. In our study, all three cell line samples
contained LOX (Accession number J9NZK5_CANLF). In the OSA8 samples, an
ANOVA test revealed that there were significantly greater LOX proteins present in the
0h platelet ‘exposed’ samples when compared to the 8h and control samples. Although
not statistically significant for the other cell lines, similar trends were observed for the
LOX protein in the 0h samples. This could suggest a decreased production of LOX after
exposed to the platelet proteins/lysate. LOX has been shown to work synergistically with
MMPs (matrix metalloproteinases) to aid tumor progression via ECM remodeling [1], but
MMP proteins were not able to be identified in our samples after searching for various
accession numbers associated with different MMPs.
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Fibronectin (Accession number F1P6H7_CANLF) was identified in OSA40 and
CMT28 samples. An ANOVA test revealed a significant increase in the expression of
fibronectin for samples incubated with platelet lysate for 8 hours when compared to the
0h and Control samples. Although not significant in the CMT28 cell line, a similar trend
was present. Fibronectin has been discovered to have a role in early stages of cancer
metastasis, as it has roles in mediation of collagen reorganization [48, 49].
Two proteins were found to be statistically different in both the OSA8 and
CMT28 cell lines. The first protein, collagen alpha-2 (Accession Number:
F1PHY1_CANLF), was significantly underexpressed in the OSA8 and CMT28 samples
after platelet lysate incubation. Like collagen alpha-1, collagen alpha-2 is a type 1
collagen that has a fibrillar formation function. Functions including skeletal system
development, blood vessel development, involvement in the TGF-b signaling pathway,
blood pressure regulation, organization of collagen fibrils, protein binding, and PDGF
binding were identified on GO analysis of the protein. The other protein was an
“Uncharacterized protein” (Accession number F1PBI6_CANLF) upon initial
identification, but was able to be identified as Thrombospondin 1 (TSP1) after a database
search in UniProt. Thrombospondin 1 had increased expression in the OSA8 and CMT28
cells after 8 hours of platelet lysate exposure. TSP1 is a protein that can be found within
platelet alpha granules and is released upon platelet activation. More recent studies have
illustrated the anti-angiogenic function and effect of TSP1 on different types of tumor
cells - overall representing a host response to attempt to prevent the angiogenic switch by
tumor cells [50]. Interestingly, though, the 0h control samples did not see a significant
change in TSP1 levels after being exposed to, but not incubated with, the same platelet
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lysate, therefore eliminating the possibility of activated platelets having been used for the
samples. The TSP1 thus appears to have had a tumor cell line source.
OSA8 up-regulated proteins
In OSA8 cell line samples, increased expression of topoisomerase II, polypeptide
N-acetylgalactosaminyltransferase, small nuclear ribonucleoprotein polypeptide A (as
well as the previously mentioned thrombospondin-1) were identified after incubation
with platelet lysate. Topoisomerase II (TOPII) has an important function in the
unwinding of DNA during replication and transcription, via its ability to cut a single
strand of DNA’s phosphate backbone. This allows unwinding to take place, therefore
preventing overwinding ahead of the replication fork which would ultimately halt the
actions of the DNA or RNA polymerases. In recent years, it has been discovered that the
actions of chemotherapeutic agents such as doxorubicin and etoposide [51] specifically
target DNA Topoisomerase II to either promote formation of DNA strand breaks within
the tumor cells (TOPII poisons) or to prevent the catalytic activity of TOPII (catalytic
inhibitors) [52]. The reason as to why this protein would have increased expression after
incubation with platelet lysate is unclear. In previous publications, increased levels of
polypeptide N-acetylgalactosaminyltransferase was found to be significantly correlated
with shorter progression-free survival intervals in patients with ovarian cancer as opposed
to experiments in which the gene for polypeptide N-acetylgalactosaminyltransferase was
suppressed [53]. Small nuclear ribonucleoprotein polypeptide A is associated with
transcription and protein biosynthesis and has previously been reported to be associated
with tumors including hepatocellular carcinomas [54]. Increases of this protein in
samples of OSA cells after incubation with platelet lysate could indicate the progression
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of tumor cells towards replication and growth. In addition to the decreased collagen
alpha-1 seen for all three cell lines, decreased protein expression of an ‘uncategorized
protein’ (Accession number E2RLJ3_CANLF) and collagen alpha-2 were identified for
the OSA8 cell line samples after incubation with platelet lysate. No additional
information could be determined about the protein identified with accession number
E2RLJ3_CANLF upon multiple database searches. Details about the collagens identified,
including this one, were detailed previously in the discussion section.
OSA8 down-regulated proteins
Three proteins (collagen alpha 1 type 1, uncategorized protein (accession number
E2RLJ3_CANLF), and collagen alpha 2 type 1) were identified as being significantly
decreased in samples after platelet lysate incubation took place as compared to the
control samples. Both of these collagens were discussed in greater detail above.
Information is limited in the literature regarding the uncategorized protein with accession
number E2RLJ3_CANLF (gene name LSM12), but there are reports of this protein
playing an active role in translation machinery, and the protein has been localized to
stress granules (cytoplasmic mRNP granules) [55, 56]. Suggested roles of LSM12 may
include mRNA degradation or tRNA splicing [57]. Current literature does not describe a
role of LSM12 with regards to any type of neoplasia or tumor cell line. In our study, a
decrease in the amount of LSM12 present after incubation with platelet lysate could
suggest a decreased cellular stress response.
OSA40 up-regulated proteins
Many proteins (Plasminogen activator inhibitor 1 precursor, Fibronectin,
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Proteasome subunit beta type 4, Mg/Mn dependent protein phosphatase 1F, Zinc-finger
CCCH-type containing 4, Solute carrier family 3, and Replication protein A2) were
identified as having significantly increased expression in the OSA40 cell line after
platelet lysate incubation. Plasminogen activator inhibitor 1 (PAI-1) is a well-studied
protein due to its numerous physiologic effects including inhibition of fibrinolysis, cell
migration, cell signaling, and, more recently, effects on tumor development [58]. PAI-1
can be produced by both normal, nonmalignant cells as well as tumor cells. PAI-1 has
been shown to have a dose-dependent proangiogenic activity associated with a negative
prognosis when elevated in human cancer patients [59, 60, 61, 62]. Various studies have
illustrated that PAI-1 can also protect and prevent various cancer cells from apoptosis as
well [63, 64, 65]. In mouse studies, suppression of PAI-1 led to poor tumor uptake by the
mice and slower tumor growth [63, 66, 67, 68]. Increased expression of PAI-1 by OSA40
cells after incubation with platelet lysate suggests that platelet proteins had a protumorigenic effect on the cells in vitro as compared to cells not exposed to any platelet
proteins or those simply washed with the proteins but not incubated for a time period.
Fibronectin is an ECM protein that has multiple physiologic roles in wound
healing, neovascularization, and angiogenesis, as well as pathologic roles including
fibrosis and cancer [69]. Studies have shown increased concentrations of fibronectin in
the presence of tumors, especially within the tumor stroma [70, 71, 72]. Platelets have
been shown to enhance the assembly of fibronectin via their lysophosphatidic acid which
mediates Rho-activated stress fiber formation and enhances fibronectin matrix assembly
[73, 74]. Fibronectin undergoes conformational changes and alternative splicing which
ultimately leads to promotion of tumorigenesis and neovascularization for metastases
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[69]. Fibronectin had a statistically significant increase in protein expression for OSA40
cells following platelet lysate incubation, which is in agreement with previous research.
The presence of platelet lysate had a directly positive impact on the production of
fibronectin in these samples.
Proteasome subunit beta type 4 (PSMB4) has been established to be responsible
for assembly of the proteasome. Proteasomes function to degrade various proteins via
proteolysis which is a feature required in numerous proliferative and anti-apoptotic
pathways by tumors [75, 76, 77, 78]. Proteosomes have therefore been targeted in
therapeutic research with current therapies against the PSMB5, PSMB6, and PSMB7.
Targeting PSMB4, though, would potentially prevent catalytic activity of all three of
these subunits, making it a novel potential therapeutic target [79, 80, 81]. Zheng et al
recently demonstrated the overexpression of PSMB4 in human multiple melanoma
plasma and cell lines as well as positive correlation between upregulation of PSMB4 on
cell proliferation and colony formation [82]. In our canine OSA40 cell samples,
incubation with platelet lysate resulted in an increased expression of PSMB4, suggesting
a pro-tumor effect on the OSA40 cells based on this finding and previous research
published on the effects of PSMB4 in tumor progression.
Mg/Mn dependent protein phosphatase 1F (PPM1F) is a serine/threonine
phosphatase that has been found to be overexpressed in invasive forms of human breast
cancer cells [83]. PPM1F promotes cell migration and metastasis as described by Susila
et al [84]. Silencing of the PPM1F gene resulted in reduced cell migration and
invasiveness [85]. In our samples, OSA40 cells incubated with platelet lysate had an
increased expression of PPM1F as compared to other control samples. This finding fits
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with platelet proteins having a pro-tumor effect overall on the OSA40 cells via promoting
up-regulation of this protein associated with cell migration and metastasis.
The protein "Zinc Finger CCCH-type Containing 4" was found to have increased
expression in OSA40 cells after incubation with platelet lysate. Specific details regarding
the gene name (ZC3H4) in association with tumor cells was not evident in the literature,
but a similar protein that has similar translational properties in the cell, Zinc finger
CCCH-type containing 15 (ZC3H15), increases hepatocellular carcinoma (HCC) growth
and overall suggests a poor prognosis when elevated following surgical resection [86].
Increased expression levels of ZC3H4, a similar protein within the same family as
ZC3H15, shows a potential role of this protein in having similar effects as well as being
up-regulated by the presence of platelet proteins, promoting tumor growth overall.
RPA2 (Replication Protein A2) upregulation in breast cancer cell lines has been
shown to promote cell proliferation, adhesion, migration, invasion, as well as induction of
EMT [87]. This protein has increased expression in OSA40 cells after incubation with
platelet lysate in vitro, suggesting platelet proteins promote these pro-neoplastic functions
for this particular cell line.
OSA40 down-regulated proteins
Decreased protein expression of NADH Dehydrogenase (ubiquinone) 1 subunit
C2 and an ‘uncategorized protein’ (Accession number J9P558_CANLF) were identified
in samples from the OSA40 cell line. The ‘uncategorized protein’ was identified as
nuclear transport factor 2 (NTF2) after searching via UniProt database. NTF2 is a protein
that promotes efficient nuclear import by a cell through its ability to bind and recycle
RanGDP. NTF2 translocates RanGDP back into the nucleus for conversion to RanGTP to
151

be used to release imported molecules bound to importin proteins [88, 89, 90]. Recent
reports in the literature have shown a correlation between decreased NTF2 expression
and tumor progression associated with increased nuclear size. In addition, increases in
NTF2 levels found in melanoma cells resulted in decreased nuclear size [91]. The
decreased expression of NTF2 by OSA40 cells after being incubated with platelet lysate
suggests that the platelet proteins had an inhibitory effect on the production of NTF2 by
the tumor cells, therefore creating a ‘protumor’ environment for the tumor cells by
reduced inhibition of nuclear growth. NADH dehydrogenase (to be abbreviated using
gene name: NDUFC2) has a critical role in cell physiology within the mitochondria.
NDUFC2 transports electrons via NADH oxidation and then reduces ubiquinone [92, 93].
In human research, NDUFC2 has been associated with many neonatal diseases as well as
malignancies including breast, colon, and thyroid cancers [94, 95, 96, 97]. Igci et al
reported down regulation of the NDUFC2 gene in thyroid carcinomas [98], while
amplification in the NDUFC2 gene region correlated with worse prognosis in estrogen
receptor negative breast cancer [99]. In our OSA40 samples, the platelet lysate caused an
interesting down regulation in the expression of NDUFC2. This effect was not repeated
(not statistically significant) in the other two cell lines studied, suggesting a specific
effect with the OSA40 cells alone. Research is still needed on the details and trends
associated with NDUFC2 and different neoplasms since current literature shows various
results for this protein and gene expression.
CMT28 up-regulated proteins
The CMT28 cells incubated with platelet lysate had significantly increased
amounts of four proteins (thrombospondin-1, ubiquitin-conjugating enzyme E2C, small
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ubiquitin-related modifier 2, nuclear casein kinase and cyclin-dependent kinase substrate
1). The function of ubiquitin-conjugating enzyme E2C (UBE2C) in the M phase of the
cell cycle contributes to cell cycle progression as well as genetic stability [100]. Normally
present in low levels in healthy tissues, increased expression and abundance has been
found for several different tumor types including breast carcinomas with a high
suggestive role in cancer progression [101, 102]. Nuclear casein kinase and cyclindependent kinase substrate 1 (NUCKS1) is a protein that has been identified as having an
important role in cell cycle progression and over-expression of NUCKS1 has been
identified in several different cancers [103, 104, 105, 106, 107, 108]. In our study,
platelet proteins appear to play a role in increasing expression of both UBE2C and
NUCKS1 in CMT28 cells, which may promote tumor cell proliferation and progression.
Small ubiquitin-related modifier 2 (SUMO3) is a protein involved in a process known as
sumolyation – an important post-translational modification – that has been associated
with the development of HCC [109]. Some studies have shown that over-expression of
SUMO proteins caused a decreased proliferation of tumor cells with little effect on
migration (same). In contrast, a study by Yang et al illustrated that silencing SUMO
protein expression in glioblastoma cells led to blocked DNA synthesis, cell growth, and
clonogenic cell survival [110]. In our samples of CMT28 cells incubated with platelet
lysate for 8 hours, significant increases in SUMO3 protein were detected. Based on the
majority of other increased protein expression and their associations with tumor cell
survival, this finding seems to fit with the pro-tumor function of SUMO3 and other
SUMO proteins identified in some studies in the literature and further suggests that
platelet proteins have a positive effect on tumor cells to allow increased expression to
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take place.
CMT28 down-regulated proteins
Incubation with platelet lysate resulted in a significant decrease in expression of
seven proteins (collagen alpha 1 type I, collagen alpha 2 type I, collagen alpha 1 type III,
collagen alpha 1 type V, uncategorized protein (accession number F1PKU9_CANLF),
NIN1/RPN12 binding protein 1 homolog, DEAH (Asp-Glu-Ala-His) box polypeptide 15)
in samples using the CMT28 cell line. The associations with collagen in the tumor
microenvironment and growth were previously discussed. Interestingly, silencing and
down regulation of NOB1 (NIN1/RPN12 binding protein 1 homolog) has been shown to
inhibit growth and proliferation of various tumor cells [111, 112]. NOB1 is closely
related to regulation of the cell cycle and transcription with involvement in many
different tumors. Recently, specific targeting of NOB1 resulted in inhibition of cell
growth in gastric cancer [113]. Decreased expression of NOB1 in our CMT28 samples
after platelet lysate incubation suggests platelet proteins having an inhibitory role in this
case by causing a down regulation of this protein that has been found to have tumorpromoting properties. DEAH (Asp-Glu-Ala-His) box polypeptide 15 (DHX15) is a
member of the DEXD/H box helicase family that plays important roles in the immune
system response to viral infection. Increased expression led to inhibition of proliferation
and metastasis in gastric cancer in a study by Xiao et al [114]. In our CMT28 cell
samples incubated with platelet lysate, decreased expression of DHX15 illustrates effects
of platelet proteins that promote tumor cell proliferation and metastasis by decreasing
amounts of this inhibitory protein found.
154

Conclusions
Overall, most of the changes seen in the proteins found to have increased or
decreased expression after incubation with platelet lysate have previously been
established in the promotion of tumor cell growth, cell migration, and metastasis. Many
of the proteins in our study that were present at statistically higher levels following
incubation with platelet lysate for 8 hours have been studied or noted for their roles in
aiding tumor cell survival and the progression of cancer. In addition, many of the proteins
found to be down regulated or have decreased expression after incubation with platelet
lysate were often proteins previously shown to have inhibitory or negative effects on
tumor cell survival. Some proteins (collagen alpha 1, collagen alpha 2, thrombospondin
1) shared the same significant up- or down-regulation for more than one tumor cell line.
This finding could suggest that similar changes are seen in protein expression across
different types of tumors including sarcomas and carcinomas.
In contrast, there were two notable proteins, thrombospondin 1 and NIN1/RPN12
binding protein 1 homolog, whose changes following platelet lysate incubated fit more
with a negative response to tumor cell growth, survival, and metastasis based on previous
findings in the literature in their roles and trends with various cancers. These negative
tumor cell responses were both seen in the CMT28 cell line samples while an increase in
thrombospondin 1 (an anti-tumor response) was also seen in the OSA8 cell line. An
increased occurrence of this response in the CMT28 cell line could suggest that
mammary tumors are more easily subjected to the protective and host response factors
present in platelets themselves along with the other proteins and factors that can aid
tumor cells in their development and progression – overall leading to a mixed response of
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the tumor cells to the platelet contents. In addition, this finding could also suggest that
perhaps osteosarcoma cells are more resistant to these host response protective measures
and more easily favor the pro-tumor effects from the platelet contents provided. This
could also fit clinically as osteosarcomas are such aggressive tumors with rapid
metastasis and poor prognosis. In addition to these theories, the nature of the conflicting
responses in protein expression and tumor survival effect could be due to the exposure of
the tumor cells to the entire platelet content rather than particular components selectively
released if the platelets were intact and in an in vivo setting.
Extended time (8 hours in this case) exposed to platelet proteins leads to various
changes and responses of tumor cells in the proteins that they produce. The majority of
the protein changes identified as significant were those that had an overall positive effect
on tumor survival and metastasis based on current literature findings for each of the
significant proteins discussed. Most proteins found to be increased following platelet
lysate incubation promote tumor cell survival and migration. Most of the proteins that
were found to have decreased production or were suppressed following incubation with
platelet lysate inhibit or prevent tumor cell survival and progression. Merely exposing the
tumor cells to, but not incubating them, with the platelet lysate did not produce the
significant changes in protein expression. This indicates that the changes produced
require time for the platelet contents to be in contact with the tumor cells and their
environment.
This information is in agreement with other research illustrating the important and
complex roles that platelets play in the tumor microenvironment, tumor growth, and
metastasis by promotion of cell migration and EMT. Interpretation of results, however,
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must take into consideration the appropriate use of statistical tests in the large data sets
seen with proteomics, and the P-values used. In our case, a P-value of 0.05 was used to
determine which findings were significant or not. While a P-value of 0.05 provides a 95%
confidence that observed changes in proteins are, in fact, correctly identified and
significant, there is a 1 in 20 chance that each of these results are in fact random
occurrences. In order to confirm these results and to identify those proteins that are truly
significantly altered, further studies would be required. One of the simplest confirmatory
tests would be to test the findings’ repeatability via repeating the experiments, to see if
the same proteins were identified as significantly increased or decreased in levels of
expression following incubation with platelet lysate. Alternatively, simply changing the
way in which the data is presented could offer increased confidence in the significance of
the findings. An example of this would be to consider the P-value for each individual data
point rather than looking at all of the proteins that fall within the P-value <0.05 category.
Observing data for their individual P-values would mean that a P-value of 0.0001 would
be more likely to be represent a real change that a P-value 0.001, which is still more
likely to indicate a real effect than a P-value of 0.05. The proteins could be ranked based
on the ‘weight’ of their significance associated with their specific P-value. In addition,
further detailed studies could be conducted looking at specific protein levels and
expression in smaller studies, using different methodologies such as immunofluorescent
assays (IFA) or other similar methods.
Interestingly, our study found that not all protein changes fit with an overall protumor response. This suggests and further illustrates the dynamic nature of cancer itself,
and how there are multiple mechanisms occurring in response to the proteins and
157

contents found within and on platelets, therefore potentially producing ambiguous
responses following platelet exposure. This information supports various findings within
the literature illustrating the various different functions of proteins found within the
different platelet granules, as well as differential release of platelet granular content based
on the stimulus at hand. In this case, the entire platelet was lysed, exposing the tumor
cells to all the contents present within and making up the platelet itself, including those
proteins that may be pro- or anti-tumor in nature that would not be in contact with the
tumor cells in all in vivo situations.
Further analyses or experiments are needed to confirm the value of the findings
described here. Overall, though, it does appear that canine platelets stimulate changes in
protein expression of various canine tumor cell lines.
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Accession Number
CO1A1_CANLF
E2RLJ3_CANLF
F1Q2M4_CANLF
F1P835_CANLF
F1PBI6_CANLF
F1PFC6_CANLF
F1PHY1_CANLF
F1PUI4_CANLF
F1P6H7_CANLF
E2RBR6_CANLF
J9P558_CANLF
E2R912_CANLF
E2RSL2_CANLF
F1PRC5_CANLF

Collagen α1

Uncharacterized Protein

DNA Topoisomerase IIα

Polypeptide N-acetylgalactosaminyltransferase
Thrombospondin 1

Small Nuclear Ribonucleoprotein Polypeptide A
Collagen α2

Plasminogen Activator Inhibitor 1 Precursor
Fibronectin

Proteasome subunit β-type

Nuclear Transport Factor 2

Protein Phosphatase, Mg2+/Mn2+ dependent

Zinc finger CCCH-type

Solute Carrier Family 3

SLC3A2

ZC3H4

PPM1F

NUTF2

PSMB4

FN1

SERPINE1

COL1A2

SNRPA

THBS1

GALNT2

TOP2A

LSM12

COL1A1

Gene Name

Significantly different proteins following incubation with platelet lysate.
Protein

Table 5.1
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⬇

⬆

⬆

⬆

⬆

⬇

⬇

OSA8

⬆

⬆

⬆

⬇

⬆

⬆

⬆

⬇

OSA40

⬇

⬆

⬇

CMT28

160

E2RLB6_CANLF
F1PG69_CANLF
F1PHX8_CANLF
E2RN95_CANLF
E2RGN5_CANLF
F1PKU9_CANLF
E2RBA4_CANLF
F1P9H9_CANLF
E2R2U3_CANLF

NADH Dehydrogenase 1 subunit C2
Collagen α1 Type III
Collagen α1 Type V

Ubiquitin-conjugating enzyme E2C

Small Ubiquitin-related Modifier 2
Uncategorized Protein

NIN1/RPN12 Binding Protein 1 Homolog

Nuclear Casein Kinase and Cyclin-dependent Kinase Substrate 1

DEAH (Asp-Glu-Ala-His) Box Polypeptide 15

DHX15

NUCKS1

NOB1

N/A

SUMO3

UBE2C

COL5A1

COL3A1

NDUFC2

RPA2
⬇

⬆

⬇

⬆

⬇

⬇

⬆

⬆

⬇

⬇

This table lists all proteins found to be significantly increased or decreased in expression following incubation with platelet lysate
for 8 hours as compared to control samples. The protein name, accession number, associated gene name, and an arrow representing
increased (⬆) or decreased (⬇) expression is shown.

E2RQP7_CANLF

Replication Protein A2

Table 5.1 (Continued)

Significant increased or decreased protein fold changes following platelet lysate incubation.

This graph shows the proteins found to be significantly increased or decreased following incubation with platelet lysate for 8 hours in
vitro for each of the three tumor cell lines used in the study. The y-axis shows the name of the protein and the x-axis displays the fold
change difference for protein expression in the samples incubated with platelet lysate for 8 hours as compared to the control samples.

Figure 5.1
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FINAL CONCLUSIONS
While animal models of human disease, like the mouse, have proven to be a
valuable contributor in the history of medical research due to their abilities to elucidate
details behind chemical signaling and biomechanisms, their translation to clinical
applications in humans can be deficient. Limitations to the mouse model include the
requirement to induce various disease states and tumors via immunosuppression,
inoculation, and implantation. Genetic variants and mutants have been developed to
allow the study of various cellular mechanisms and the results of gene suppression or
deletions. The dog, on the other hand, is a species that shares many of the same naturally
occurring diseases as humans, including neoplasias like lymphoma, osteosarcoma,
mammary tumors, prostate cancer, and mast cell tumors [1, 2, 3] – therefore avoiding the
need to artificially induce different disease states, suppress the immune system, or create
genetic alterations. Dogs share the same environment as humans which, therefore,
exposes them to the same potential environmental triggers and carcinogens for cancer
development (e.g. cigarette smoke, pesticides, UV exposure). In addition, dogs share
many of the same clinical presentations, biological behavior, hormonal influences,
histopathologic appearances, response to treatments, and prognosis in many of the tumors
found to naturally affect humans.

172

Platelets have been shown to play various roles in different cancers affecting
different species. While limited research is currently available regarding the roles of
platelets in canine tumor development, growth, and metastasis, similarities shared
between dog and human tumors such as lymphoma, osteosarcoma, and mammary tumors
offer an important opportunity for the research and discovery of new information that
will benefit both veterinary medicine and human medicine. While limited canine cancer
proteomic studies are available currently, promise has been shown in the identification of
potential biomarkers for various cancers that highlight the value of proteomics in the
future of cancer research as well as the value of the dog as an excellent model of human
cancers. The application of proteomics research in platelet-tumor cell interactions holds
promise for uncovering the mechanisms and protein components by which platelets are
involved in cancer.
At the beginning of this study, limited information existed regarding
methodologies for obtaining highly purified samples of canine platelets from relatively
small (clinically relevant) blood samples. Since platelets are anucleate cells with much
less protein and mRNA than other blood cells, particularly leukocytes, future research
into platelet-tumor cell interactions required that a pure platelet sample be obtainable.
Clinical relevance was important for this study, as the ability to collect small samples of
whole blood from clinical patients for potential use in serial monitoring of platelet
samples was desirable.
With one of the main goals being to perform proteomic studies looking at platelettumor cell interactions, the lack of any known research into the canine platelet proteome
created the motivation for the second part of this study. The first normal canine platelet
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proteome was described using function and pathways analyses. Differential detergent
fractionation, a novel and less widely used methodology for protein digestion in
proteomic analysis, was utilized to ensure comprehensive yields of membrane, basic,
high molecular weight, and signaling proteins compared to 2D electrophoretic methods
that may limit these protein findings [4, 5].
In the last chapter of this study, evidence of the direct impact that platelet contents
have on tumor cell expression of proteins was described for two tumor types
(osteosarcoma and mammary tumors) that have a valuable role as canine models of
human cancer. Most of the protein expression alterations that were found have been
described as having positive effects on tumor cell survival, growth, and metastasis
elsewhere in the literature for studies conducted in other species. Interestingly, some
significant changes in protein expression have been linked to negative or anti-tumor
effects elsewhere in the literature. Lack of direct information regarding the roles and
mechanisms that these various proteins play in canine platelets and canine cancers,
however, poses a gap in the research as comparisons often had to be made based on
findings from human and mouse studies.
Since platelet lysate was utilized in the last study, additional experiments would
be value utilizing either whole, intact platelets or platelet releaseate. Performing
additional experiments using the products of activated platelets rather than platelet lysate
would allow comparisons to be made looking at the effects of platelet activation on tumor
cell protein expression, as many studies in the literature have shown that platelets are
activated directly or indirectly by tumor cells [6, 7]. To do this, platelets could be
activated after collection and purification using known platelet activators like collagen,
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thrombin, or ADP, centrifuged to remove the platelets, and the releaseate added to tumor
cell samples in vitro. In addition, whole platelets could be added to the tumor cell
samples in vitro to see the effects of direct intact platelet contact with tumor cell protein
expression, although preliminary studies have proven difficult in this regard as clot
formation is a critical obstacle to overcome experimentally. Excessive wash steps are
undesirable in platelet studies as activation could occur during attempts to separate the
platelets from the tumor cells for proteomic analysis, altering the protein composition of
the samples collected before analysis and not truly representing the effects of the platelets
on the tumor cells.
Many of the findings presented by the work done in these studies leave questions
unanswered, as this niche in the world of canine platelet proteome research with regards
to tumor cell interactions and models of human cancer has to date attracted very little
research. These initial findings have proven that canine platelet contents do stimulate
tumor cell changes in protein expression, the effects of which may be contrasting in
nature with regards to tumor cell survival or death. Many of the proteins that were
identified as having significant alterations in expression could be monitored and studied
individually for the specific roles that they play in the physiology of different canine
cancers. In addition, changes that occur within the platelet itself following tumor cell
exposure could be studied at the level of the proteome. This could potentially identify
alterations in the platelet as a result of tumor cell direct contact or signaling proteins, and
could aid in identifying increases and decreases in protein expression in response to the
tumor cell presence. Since most current studies show evidence that platelets promote
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tumor metastasis [8-11], it would be interesting to see the feedback and stimulation
occurring from the tumor cell to the platelet itself.
Ideally, in the future this research will lead to clinical case applications. Serial
monitoring of canine platelet proteomes from cancer patients at the time of diagnosis,
during treatment, at and following remission, and until relapse would provide critical
information about changes in platelet protein expression throughout the course of cancer
development and treatment. Since many of the naturally occurring cancers that dogs
share with humans tend to recur following treatment (lymphoma, osteosarcoma,
mammary tumors), this could lead to identification of biomarkers for early return of
cancer from remission. Identifying relapses before they are clinically apparent would aid
in quicker treatment and potentially increased survival times and prognosis overall.
In conclusion, the technique described allows the collection of highly pure platelet
samples from small volumes of canine whole blood, which is important for highly
sensitive methods like proteomics. The results from the proteomic studies described here
have revealed that canine platelet contents stimulate various changes in protein
expression by select canine osteosarcoma and mammary tumor cell lines in vitro. Our
findings describe initial mapping of the canine platelet proteome as well as suggest that
platelets most likely have a positive role in tumor cell growth in dogs.
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The following supplemental files were created using Microsoft Office Excel for
Mac 2016 (Version 15.20) and saved as PDF files. The PDF files were compressed into a
.rar file using WinRAR. They can be accessed on the Mississippi State University
Electronic Thesis and Dissertation Database, available at
http://sun.library.msstate.edu/ETD-db/. Once downloaded, the files can be extracted
using an unzipping program such as WinRAR or WinZip. Files can be viewed using
Adobe Reader software or other software for viewing PDF files.
Supplemental File 1: Protein List from Normal Canine Platelet
A list of all unique proteins identified from platelets collected from three healthy
dogs. Included in the file is a list of accession numbers and the protein description if
available.
Supplemental File 2: Tumor Cell Proteins
A list of all the proteins identified from the three different tumor cells lines used
in the study in Chapter V. Included in the file is a list of accession numbers and protein
descriptions when available for the OSA8, OSA40, and CMT28 cell samples.
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